GSK plc 6-K, filed Feb 5, 2025
GSK plc (GSK)
6-K
2025-02-05
For: 2025-02-05
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on February 5, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
|
GSK delivers strong 2024 performance
with further improvement to long-term growth
outlook
|
|
|
|
|
|
Strong sales and Core EPS growth reflecting accelerating momentum
in Specialty Medicines offsetting lower Vaccine sales
|
|
|
●
|
Total
2024 sales £31.4 billion +3% AER; +7% CER
|
|
●
|
Specialty
Medicines sales +19%. HIV sales +13%. Oncology +98%.
Respiratory/Immunology and Other +13%
|
|
●
|
Vaccines
sales -4%. Shingrix +1% and
Arexvy -51%
|
|
●
|
General
Medicines sales +6%. Trelegy +27%
|
|
●
|
Total
operating profit -33% and Total EPS -40% largely driven by
£1.8 billion ($2.3 billion) charge relating to settlement of
Zantac
litigation
|
|
●
|
Core
operating profit +11% (with further positive impact of +2% ex
COVID) and Core EPS +10% (with further positive impact of +2% ex
COVID) reflecting strong Specialty Medicines performance and
disciplined increased investment in progressing the R&D
portfolio
|
|
●
|
Cash
generated from operations in the year of £8 billion with Free
cash flow of £3 billion
|
|
(Financial
Performance – 2024 results unless otherwise stated, growth %
and commentary at CER as defined on page
50).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
Q4 2024
|
||||||||
|
|
£m
|
|
%
AER
|
|
%
CER
|
|
£m
|
|
%
AER
|
|
%
CER
|
|
Turnover
|
31,376
|
|
3
|
|
7
|
|
8,117
|
|
1
|
|
4
|
|
Turnover ex COVID
|
31,364
|
|
4
|
|
8
|
|
8,106
|
|
1
|
|
4
|
|
Total
operating profit
|
4,021
|
|
(40)
|
|
(33)
|
|
696
|
|
21
|
|
54
|
|
Total
operating margin %
|
12.8%
|
|
(9.4ppts)
|
|
(8.3ppts)
|
|
8.6%
|
|
1.5ppts
|
|
3.4ppts
|
|
Total
EPS
|
63.2p
|
|
(48)
|
|
(40)
|
|
10.1p
|
|
18
|
|
60
|
|
Core
operating profit
|
9,148
|
|
4
|
|
11
|
|
1,431
|
|
(18)
|
|
(10)
|
|
Core
operating margin %
|
29.2%
|
|
0.2ppts
|
|
0.9ppts
|
|
17.6%
|
|
(4.1ppts)
|
|
(2.9ppts)
|
|
Core
EPS
|
159.3p
|
|
3
|
|
10
|
|
23.2p
|
|
(20)
|
|
(10)
|
|
Cash
generated from operations
|
7,861
|
|
(3)
|
|
|
|
2,586
|
|
(30)
|
|
|
|
|
|
|
Further progress in R&D with growth prospects strengthened in
all key therapeutic areas:
|
|
|
●
|
71
Specialty Medicines and Vaccines now in clinical development,
including 19 in phase III/registration
|
|
●
|
Excellent
pipeline progress in 2024 with 13 positive phase III readouts
across Respiratory, Immunology & Inflammation; Oncology; HIV
and Infectious Diseases
|
|
●
|
Continued
targeted business development to support future growth: proposed
acquisition of IDRx, Inc. (GI cancers); acquisition of Aiolos Bio
(asthma) and new research alliance with Flagship Pioneering
(Respiratory, Immunology & Inflammation), plus strengthened
platform capabilities through acquisition of Elsie Biotechnologies
(oligonucleotides)
|
|
●
|
5 major
new product approvals expected in 2025 including: Blenrep (multiple myeloma) and
depemokimab (severe asthma and CRSwNP(1)); plus phase III
readouts: camlipixant (refractory chronic cough) and tebipenem
(complicated UTI); and important pipeline catalysts: Respiratory
(depemokimab COPD); Oncology (B7-H3 & B7-H4 ADCs); HIV (ULA
Q4/Q6M)
|
|
|
|
|
Increased returns to shareholders
|
|
|
●
|
Q4 2024
dividend of 16p declared; 61p FY 2024; 64p expected for
2025
|
|
●
|
£2
billion share buyback programme to be implemented over the next 18
months
|
|
|
|
|
2025 guidance and further improvement to long-term
outlooks
|
|
|
●
|
Expect
2025 turnover growth of between 3% to 5%; Core operating profit
growth of between 6% to 8%; Core EPS growth of between 6% to 8%,
including the expected benefit from the share buyback
programme
|
|
●
|
2031
sales outlook increased to more than £40 billion (previously
>£38 billion), reflecting late-stage pipeline
progress
|
Guidance all at CER
|
|
|
Emma Walmsley, Chief Executive Officer, GSK:
“GSK
delivered another year of excellent performance in 2024, with
strong sales and core profit growth driven by accelerating momentum
of our specialty medicines portfolio. This, together with
outstanding phase III pipeline progress, means we expect another
year of profitable growth in 2025, and have further improved our
long-term outlook, with sales of more than £40 billion now
expected by 2031. In particular, we are increasing and prioritising
R&D investment to promising new long-acting and specialty
medicines in Respiratory, Immunology & Inflammation, Oncology
and HIV. Our outperformance and stronger balance sheet support
these investments and others planned in R&D, as well as the
opportunity to enhance shareholder returns through our progressive
dividend and the share buyback programme which we have set out
today.”
|
The Total results
are presented in summary above and on page 7 and Core results
reconciliations are presented on pages 19, 20, 22 and 23. Core
results are a non-IFRS measure that may be considered in addition
to, but not as a substitute for, or superior to, information
presented in accordance with IFRS. The following terms are defined
on pages 50-51: Core results, £% or AER% growth, CER% growth,
COVID-19 solutions, turnover excluding COVID-19 solutions; and
other non-IFRS measures. GSK provides guidance on a Core results
basis only, for the reasons set out on page 17. ll
expectations, guidance and targets regarding future performance and
dividend payments should be read together with ‘Guidance and
outlooks, assumptions and cautionary statements’ on page 52.
(1) CRSwNP - Chronic rhinosinusitis with nasal
polyps.
2025 Guidance
GSK
provides its full-year guidance at constant exchange rates
(CER).
|
|
|
Turnover is expected to increase between 3 to 5 per
cent
|
|
Core operating profit
is expected to increase between 6 to 8
per cent
|
|
Core earnings per share
is expected to increase between 6 to 8
per cent
|
This
guidance is supported by the following turnover expectations for
full-year 2025 at CER
|
|
|
|
|
Specialty Medicines
|
–
|
expected
increase of a low double-digit per
cent in turnover
|
|
Vaccines
|
–
|
expected
decrease of a low single-digit per
cent in turnover
|
|
General Medicines
|
–
|
expected
to be broadly stable for
turnover
|
Core
operating profit is expected to grow between 6 to 8 per cent at
CER. GSK expects to deliver leverage at a gross margin level due to
improved product mix from Specialty Medicines growth and continued
operational efficiencies. In addition, GSK anticipates further
leverage in Operating profit as we continue to take a returns-based
approach to SG&A investments. R&D is expected to increase
broadly in line with sales as we invest for future
growth.
Core
earnings per share is expected to increase between 6 to 8 per cent
at CER, in line with Core operating profit growth, reflecting
higher interest charges and the tax rate which is expected to rise
to around 17.5%, offset by the expected benefit of up to 1% from
the share buyback programme. Expectations for non-controlling
interests remain unchanged relative to 2024.
Dividend policy
The
Dividend policy and the expected pay-out ratio remain unchanged.
Consistent with this, and reflecting strong business performance
during the quarter, GSK has declared a dividend for Q4 2024 of 16p
per share and 61p per share for the full year 2024. GSK's future
dividend policy and guidance regarding the expected dividend
pay-out in 2025 are provided on page 36.
GSK now
intends to commence a £2 billion share buyback programme, to
be implemented over the next 18 months.
COVID-19 solutions
For the
full year 2025, GSK does not anticipate any further COVID-19
pandemic-related sales or operating profit. For the full year 2024,
and in comparison to 2023, the full year growth in Sales and Core
operating profit was adversely impacted by one and two percentage
points, respectively.
2021-2026 and 2031 Outlooks
By
2031, GSK now expects to achieve sales of more than £40
billion (previously >£38 billion) on a risk-adjusted basis
and at CER. This further increase reflects the inclusion of
Blenrep, the significant
phase III progress since last year and multiple launch
opportunities in the 2025 to 2031 period.
As
before, we have further upside potential from our early-stage
pipeline and prospective business development.
There
is no change to our Group outlooks for 2021-2026. GSK continues to
expect sales to grow more than 7% on a CAGR basis and Core
operating profit to increase more than 11%, on the same basis. Core
operating profit margin in 2026 continues to be expected to be more
than 31%.
All
expectations, guidance and outlooks regarding future performance
and dividend payments should be read together with ‘Guidance
and outlooks, assumptions and cautionary statements’ on page
52.
These
outlooks are provided at CER and exclude any contribution from
COVID-19 related solutions.
Exchange rates
If
exchange rates were to hold at the closing rates on 29 January 2025
($1.24/£1, €1.19/£1 and Yen 193/£1) for the
rest of 2025, the estimated impact on 2025 Sterling turnover growth
for GSK would be +1% and if exchange gains or losses were
recognised at the same level as in 2024, the estimated impact on
2025 Sterling Core Operating Profit growth for GSK would be
+2%.
Results presentation
A
conference call and webcast for investors and analysts of the
quarterly results will be hosted by Emma Walmsley, CEO, at 10.45 am
GMT (US EST at 05.45 am) on 5 February 2025. Presentation
materials will be published on www.gsk.com prior to the webcast and
a transcript of the webcast will be published
subsequently.
Notwithstanding
the inclusion of weblinks, information available on the
company’s website, or from non GSK sources, is not
incorporated by reference into this Results
Announcement.
|
Performance:
turnover
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
2024
|
|
Q4 2024
|
||||||||
|
|
£m
|
|
Growth
AER%
|
|
Growth
CER%
|
|
£m
|
|
Growth
AER%
|
|
Growth
CER%
|
|
Shingles
|
3,364
|
|
(2)
|
|
1
|
|
848
|
|
(7)
|
|
(4)
|
|
Meningitis
|
1,437
|
|
14
|
|
18
|
|
295
|
|
8
|
|
12
|
|
RSV
(Arexvy)
|
590
|
|
(52)
|
|
(51)
|
|
158
|
|
(70)
|
|
(69)
|
|
Influenza
|
408
|
|
(19)
|
|
(16)
|
|
105
|
|
11
|
|
14
|
|
Established
Vaccines
|
3,339
|
|
2
|
|
6
|
|
806
|
|
5
|
|
8
|
|
Vaccines ex COVID
|
9,138
|
|
(6)
|
|
(3)
|
|
2,212
|
|
(14)
|
|
(11)
|
|
Pandemic
vaccines
|
–
|
|
(100)
|
|
(100)
|
|
–
|
|
>(100)
|
|
>(100)
|
|
Vaccines
|
9,138
|
|
(7)
|
|
(4)
|
|
2,212
|
|
(14)
|
|
(12)
|
|
HIV
|
7,089
|
|
10
|
|
13
|
|
1,969
|
|
11
|
|
14
|
|
Respiratory/Immunology
and Other
|
3,299
|
|
9
|
|
13
|
|
910
|
|
5
|
|
9
|
|
Oncology
|
1,410
|
|
93
|
|
98
|
|
408
|
|
67
|
|
72
|
|
Specialty Medicines ex COVID
|
11,798
|
|
16
|
|
19
|
|
3,287
|
|
14
|
|
18
|
|
Xevudy
|
12
|
|
(73)
|
|
(73)
|
|
11
|
|
(15)
|
|
(15)
|
|
Specialty Medicines
|
11,810
|
|
15
|
|
19
|
|
3,298
|
|
14
|
|
17
|
|
Respiratory
|
7,213
|
|
6
|
|
10
|
|
1,806
|
|
3
|
|
7
|
|
Other
General Medicines
|
3,215
|
|
(5)
|
|
–
|
|
801
|
|
(3)
|
|
3
|
|
General Medicines
|
10,428
|
|
2
|
|
6
|
|
2,607
|
|
1
|
|
6
|
|
Total
|
31,376
|
|
3
|
|
7
|
|
8,117
|
|
1
|
|
4
|
|
Total ex COVID
|
31,364
|
|
4
|
|
8
|
|
8,106
|
|
1
|
|
4
|
|
By Region:
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
16,384
|
|
4
|
|
6
|
|
4,327
|
|
(1)
|
|
1
|
|
Europe
|
6,666
|
|
2
|
|
4
|
|
1,755
|
|
6
|
|
10
|
|
International
|
8,326
|
|
5
|
|
11
|
|
2,035
|
|
1
|
|
8
|
|
Total
|
31,376
|
|
3
|
|
7
|
|
8,117
|
|
1
|
|
4
|
|
Turnover ex COVID is excluding COVID-19 solutions
during the years from 2020 to 2023 and is a non-IFRS measure
defined on page 51 with the reconciliation to the IFRS measure
Turnover included in the table above. Financial Performance –
Q4 2024 results unless otherwise stated, growth % and commentary at
CER.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
Q4 2024
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Vaccines
|
Total
|
9,138
|
(7%)
|
(4%)
|
|
2,212
|
(14%)
|
(12%)
|
|
Excluding COVID
|
9,138
|
(6%)
|
(3%)
|
|
2,212
|
(14%)
|
(11%)
|
|
Vaccines sales decreased in the year and quarter, primarily
impacted by lower demand for Arexvy related to a more limited ACIP(1) recommendation in the US and channel inventory
consumption compared to launch year stocking in 2023. Meningitis
vaccines had their strongest year of sales to date with
double-digit growth across all regions and Established vaccines
continued to grow across International and the US. Overall,
Vaccines performance was also adversely impacted due to COVID-19
solution sales and US CDC(2) stockpile replenishments in 2023, each impacting
full year growth by 1 percentage point.
|
|
|
|
|
|
|
|
|
|
Shingles
|
3,364
|
(2%)
|
1%
|
|
848
|
(7%)
|
(4%)
|
Sales
of Shingrix, a vaccine
against shingles, grew in the year with ex-US sales growth more
than offsetting lower sales in the US, but declined in the
quarter.
The US
cumulative immunisation rate reached 40%, up five percentage points
compared to 12 months earlier(3). Sales decreased
by 18% in the full year and 13% in the quarter reflecting the
slowing pace of penetration of harder-to-reach unvaccinated
consumers, partially offset by favourable pricing. Full year
Shingrix sales were also
negatively impacted by changes in retail vaccine prioritisation
partly due to a transition to a new CMS(4) rule that changed
how pharmacies process reimbursements from payers.
Shingrix grew significantly in International in the year,
driven by a national immunisation programme in Australia and supply
to our co-promotion partner in China, but declined in the quarter
reflecting lower sales in China. In Europe, Shingrix grew in both the year and
quarter driven by expanded public funding and higher uptake across
multiple countries, partly offset by lower demand in Germany.
Markets outside the US represented 56% of 2024 global sales (2023:
45%), with Shingrix
launched in 52 countries. The overwhelming majority of ex-US
Shingrix opportunity is
concentrated in 10 markets where the average immunisation rate is
around 7% with significantly higher uptake in funded
cohorts.
Footnotes:
|
(1) Advisory Committee on Immunization
Practices (2) Centres for Disease Control and
Prevention (3) Based on data from IQVIA up until the end of
Q3 2024 (4) Centers for Medicare & Medicaid
Services
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
Q4 2024
|
||||
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Meningitis
|
1,437
|
14%
|
18%
|
|
295
|
8%
|
12%
|
In the
year and the quarter, Meningitis vaccines achieved double-digit
growth. Bexsero, a vaccine
against meningitis B, achieved sales of over £1 billion for
the first time. Growth was primarily due to favourable pricing mix
and increased full year purchases from the CDC in the US,
recommendation in Germany and launch in Vietnam. Meningitis vaccine
sales growth in the quarter was also impacted by a decline in
Menveo, a vaccine against
meningitis ACWY, related to US CDC stockpile replenishment in Q4
2023.
|
|
|
|
|
|
|
|
|
|
RSV (Arexvy)
|
590
|
(52%)
|
(51%)
|
|
158
|
(70%)
|
(69%)
|
Arexvy, a RSV(1) vaccine for older
adults, declined both in the year and quarter. US sales decreased
due to lower demand partly related to a more limited recommendation
from ACIP for individuals aged 60 to 74. Full year sales were also
adversely impacted by channel inventory consumption compared to the
launch year stocking in 2023. Arexvy maintained the market leading
position in retail where the overwhelming majority of doses are
administered. More than ten million US adults(2) aged 60 and older
at risk have been protected by Arexvy since the launch in Q3
2023.
In
countries outside the US, growth in the year reflected uptake
following a positive recommendation in Germany, initial tender
deliveries in Saudi Arabia and new launch inventory builds in
Australia and Brazil, partly offset in the quarter by lower demand
in Canada. While Arexvy is
approved in 59 markets globally, 17 countries had national RSV
vaccination recommendations for older adults and 6, including the
US, had reimbursement programmes in place at the year
end.
|
|
|
|
|
|
|
|
|
|
Influenza
|
408
|
(19%)
|
(16%)
|
|
105
|
11%
|
14%
|
Fluarix/FluLaval sales decreased in the year driven by
competitive pressure and lower market demand primarily in the US,
but grew in the quarter due to pricing favourability as a result of
channel mix.
|
|
|
|
|
|
|
|
|
|
Established
Vaccines
|
3,339
|
2%
|
6%
|
|
806
|
5%
|
8%
|
Established
Vaccines grew in both the year and quarter. This reflected
increased sales of Hepatitis vaccines across all regions, higher US
market share and European demand for Boostrix and increased International
supply and US uptake of MMR/V(3) vaccines. This was
partly offset by adverse CDC stockpile movements for Rotarix and Infanrix/Pediarix. Established Vaccine
sales in 2024 included around £130 million of non-repeating
contracted sales including divested brands which have now
ceased.
|
|
|
|
|
|
|
|
|
|
|
Specialty Medicines
|
Total
|
11,810
|
15%
|
19%
|
|
3,298
|
14%
|
17%
|
|
Excluding COVID
|
11,798
|
16%
|
19%
|
|
3,287
|
14%
|
18%
|
Specialty Medicines sales grew by double-digit percentages in the
full year and in the quarter, reflecting continued growth across
disease areas, with strong performances in HIV,
Respiratory/Immunology and Oncology.
|
|
|
|
|
|
|
|
|
|
HIV
|
7,089
|
10%
|
13%
|
|
1,969
|
11%
|
14%
|
HIV
sales continue to grow double-digits for the full year and the
quarter, driven by strong patient demand for long-acting injectable
medicines (Cabenuva,
Apretude) and Dovato. This demand primarily reflects
a 2 percentage point(4) increase in market
share compared to the prior period which contributed 10 percentage
points of growth in 2024. The remainder of the full year growth was
driven by favourable in-year pricing, including the positive impact
from channel mix.
|
|
|
|
|
|
|
|
|
|
Oral
2DR
|
2,924
|
18%
|
21%
|
|
827
|
19%
|
23%
|
Sales
of Oral 2DR (Dovato,
Juluca) now represent 42% of the total HIV portfolio.
Dovato, the first and only
once-daily oral 2DR for the treatment of HIV infection in both
treatment naive and virally suppressed adults and adolescents
continues to be the largest product in the HIV portfolio with sales
of £2,239 million in 2024 and growing 27% versus
2023.
|
|
|
|
|
|
|
|
|
|
Long-Acting
Medicines
|
1,292
|
51%
|
55%
|
|
394
|
43%
|
47%
|
Long-Acting
Injectable Medicine sales in the quarter now represent 20% of the
total HIV portfolio compared to 16% for Q4 2023 and contributed
over 50% of the total HIV growth in 2024. Cabenuva, the only complete long-acting
injectable regimen for HIV treatment reached sales of £1,013
million in 2024, growing 47% due to strong patient demand across US
and Europe. Apretude, the
first long-acting injectable option for HIV prevention delivered
sales of £279 million in 2024, growing 93% compared to
2023.
Footnotes:
|
(1) Respiratory syncytial virus
(2) Based on data from IQVIA (3) Measles, mumps, rubella and
varicella (4) DoT Volume Market Share - IQVIA, GERS (France),
Czech State Institute for Drug Control (SUKL), DLI Market
Intelligence (Denmark), farmINFORM (Netherlands), Cegedim
Healthcare (Romania).
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
Q4 2024
|
||||
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Respiratory/Immunology
and Other
|
3,299
|
9%
|
13%
|
|
910
|
5%
|
9%
|
Sales
primarily comprise contributions from Nucala in respiratory and Benlysta in immunology. Double-digit
sales growth in the full year was delivered for both Nucala and Benlysta, driven by patient demand
globally across US, European and International markets. Growth in
the quarter was adversely impacted by channel inventory build on
both Nucala and
Benlysta in the US in Q4
2023.
|
|
|
|
|
|
|
|
|
|
Nucala
|
1,784
|
8%
|
12%
|
|
484
|
3%
|
7%
|
Nucala, is an IL-5 antagonist monoclonal antibody treatment
for severe asthma, with additional indications including chronic
rhinosinusitis with nasal polyps, eosinophilic granulomatosis with
polyangiitis (EGPA), and hypereosinophilic syndrome (HES).
Double-digit sales growth for the full year was driven particularly
by strong performance in Europe and International regions,
reflecting higher patient demand for treatments addressing
eosinophilic-led disease. Growth in the quarter was adversely
impacted by the US from channel pricing pressure and from channel
inventory build in Q4 2023.
|
|
|
|
|
|
|
|
|
|
Benlysta
|
1,490
|
10%
|
14%
|
|
423
|
9%
|
12%
|
Benlysta, a monoclonal antibody treatment for Lupus,
continues to grow by double-digit percentages in the full year
representing strong demand and volume growth in US, European and
International regions, with bio-penetration rates having increased
across many markets. Growth in the quarter continued at
double-digits however was slightly reduced by the impact of channel
inventory build in the US in Q4 2023.
|
|
|
|
|
|
|
|
|
|
Oncology
|
1,410
|
93%
|
98%
|
|
408
|
67%
|
72%
|
Strong
Oncology sales growth continued driven by increasing patient demand
for Zejula, a
PARP(1)
inhibitor, Jemperli, a
PD-1(2)
blocking antibody, and Ojjaara/Omjjara, a daily JAK1/JAK2 and
ACVR1(3)
inhibitor.
|
|
|
|
|
|
|
|
|
|
Zejula
|
593
|
13%
|
17%
|
|
143
|
(6%)
|
(3%)
|
Zejula, a PARP inhibitor treatment for ovarian cancer, grew
by double-digit percentages for the full year, with strong growth
delivered across all regions with sustained increases in patient
demand and higher volumes, further enhanced by positive price
impacts in the US. Growth in the quarter was adversely impacted in
the US due to favourable price impacts in Q4 2023 as a result of
channel mix adjustments. This was partly offset by continued growth
in the quarter in Europe and International regions.
|
|
|
|
|
|
|
|
|
|
Jemperli
|
467
|
>100%
|
>100%
|
|
149
|
>100%
|
>100%
|
Jemperli, a medicine for front-line treatment in combination
with chemotherapy for patients with primary advanced or recurrent
endometrial cancer, continued to grow strongly in the full year and
in the quarter. Strong sales in the quarter were driven largely by
increased patient uptake in the US, following Q3 2024 FDA approval
expanding the indication to include all adult patients with primary
advanced or recurrent endometrial cancer.
|
|
|
|
|
|
|
|
|
|
Ojjaara/Omjjara
|
353
|
>100%
|
>100%
|
|
118
|
>100%
|
>100%
|
Ojjaara/Omjjara, a treatment for myelofibrosis patients with
anaemia, grew strongly in the full year and the quarter largely
driven by the US with continued uptake in patients since its
product launch in Q3 2023. Sales in the quarter included increasing
contributions from Europe and International regions following
launches in the UK and Germany in Q1 2024, and in Japan in Q3
2024.
|
|
|
|
|
|
|
|
|
|
General Medicines
|
10,428
|
2%
|
6%
|
|
2,607
|
1%
|
6%
|
Sales include contributions from both the Respiratory and Other
General Medicine portfolios. Sales growth in the full year and the
quarter was primarily driven by Trelegy, a COPD(4) and asthma medicine, with strong demand across all
regions. Performance was adversely impacted by the removal of the
AMP(5) cap on Medicaid drug prices in the US. This
removal impacted Advair, Flovent,
and Lamictal due to significant pricing reductions, reduced
commercial contracting, and the decision to discontinue
branded Flovent. However, this has been fully offset by the
increased use of authorised generic versions of Advair and Flovent while, significantly, continuing to provide access
to patients.
|
|
|
|
|
|
|
|
|
|
Respiratory
|
7,213
|
6%
|
10%
|
|
1,806
|
3%
|
7%
|
Sales
growth in the full year and in the quarter reflected Trelegy's strong performance in all
regions. In the US adverse impacts from the removal of the AMP cap
were fully offset by the increased use of authorised generic
versions of Advair and
Flovent, providing access
to medicines for patients.
Footnotes:
(1) PARP: a Poly ADP ribose polymerase (2)
PD-1: a programmed death receptor-1 blocking antibody (3)
JAK1/JAK2 and ACVR1: once a-day, oral JAK1/JAK2 and activin A
receptor type 1 (ACVR1) inhibitor (4) Chronic obstructive
pulmonary disease (5) Average manufacturer
price
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
Q4 2024
|
||||
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Trelegy
|
2,702
|
23%
|
27%
|
|
669
|
14%
|
17%
|
Trelegy is the most prescribed SITT(1) treatment
worldwide for COPD and asthma. Sales grew 27% in the full year,
driven largely by volume growth, whilst also benefiting from
favourable pricing. Strong volume growth continued across all
regions reflecting patient demand, SITT class growth, and increased
market share. Overall favourable pricing in the full year was
driven by US channel mix price adjustments in the first six months
of 2024, which moderated in the second half, adversely impacting Q4
2024 performance.
|
|
|
|
|
|
|
|
|
|
Seretide/Advair
|
1,057
|
(7%)
|
(3%)
|
|
259
|
(6%)
|
(2%)
|
Seretide/Advair is a combination treatment used to treat
asthma and COPD. In the full year and in the quarter, sales
decreased in Europe and International reflecting continued generic
erosion by competitor products. This was partially offset by growth
in the US driven largely by favourable impacts from channel mix
adjustments.
|
|
|
|
|
|
|
|
|
|
Other
General Medicines
|
3,215
|
(5%)
|
–%
|
|
801
|
(3%)
|
3%
|
Growth
in the full year was flat, with growth in antibiotics and
dermatology in International markets offset by global declines from
continued generic competition across the portfolio. Growth of 3% in
the quarter was driven by double-digit growth of the dermatology
portfolio. The full year and quarter declines at AER were driven by
exchange movements in a number of International
markets.
By Region
|
|
|
|
|
|
|
|
|
|
|
US
|
Total
|
16,384
|
4%
|
6%
|
|
4,327
|
(1%)
|
1%
|
|
|
Excluding COVID
|
16,374
|
4%
|
6%
|
|
4,317
|
(1%)
|
1%
|
Vaccine
sales decreased in both the full year and the quarter primarily in
Arexvy due to lower demand
related to a more limited ACIP recommendation and related channel
inventory consumption compared to the 2023 launch year stocking.
Shingrix also decreased
reflecting lower demand driven by the continued challenge of
activating harder-to-reach consumers.
Specialty
Medicines double-digit growth in the full year was driven by strong
Oncology and HIV performance, and continued growth in Nucala and Benlysta. In the quarter, strong growth
continued in Oncology and HIV, performance of Nucala and Benlysta was adversely impacted by
channel inventory build-up in Q4 2023.
General
Medicine’s growth in the full year and the quarter was
primarily driven by increased demand for Trelegy, with strong volume growth from
higher patient demand and growth of the SITT market as well as
favourable price benefits. Performance continues to be impacted
following the removal of the AMP cap on Medicaid drug prices, which
particularly impacted Advair,
Flovent and Lamictal. This was fully offset by the
increased use of authorised generic versions of Advair and Flovent, providing access to medicines
for patients.
|
|
|
|
|
|
|
|
|
|
|
Europe
|
Total
|
6,666
|
2%
|
4%
|
|
1,755
|
6%
|
10%
|
|
|
Excluding COVID
|
6,665
|
4%
|
6%
|
|
1,754
|
6%
|
10%
|
Vaccine
sales grew in the year and double-digit in the quarter.
Shingrix growth was driven
by expanded public funding across several markets, partly offset by
lower demand in Germany. Bexsero and Arexvy sales increased following
recommendations in Germany.
Specialty
Medicines sales grew by double-digits in the full year and quarter
due to continued strong performance in Oncology, Benlysta in immunology, and
Nucala in respiratory
including the benefit from new indication launches. HIV growth for
the full year and the quarter continued at a high single digit
percentage.
General
Medicines sales were broadly stable in the full year and the
quarter. Strong double-digit growth for Trelegy and Anoro was offset by decreases across
other general medicine products.
|
|
|
|
|
|
|
|
|
|
|
International
|
Total
|
8,326
|
5%
|
11%
|
|
2,035
|
1%
|
8%
|
|
|
Excluding COVID
|
8,325
|
5%
|
12%
|
|
2,035
|
1%
|
8%
|
Vaccine
sales grew strongly in the year while declining in the quarter. In
the year, growth was driven by Shingrix related to the national
immunisation program in Australia and supply to our co-promotion
partner in China together with strong momentum in Meningitis
vaccines and single-digit growth in Established Vaccines sales. The
quarter was adversely impacted by lower Arexvy sales in Canada and Shingrix sales in China.
Specialty
Medicine’s double-digit growth in the full year and the
quarter was driven by HIV, Nucala in Respiratory, Benlysta in Immunology, and
Oncology.
General
Medicines sales growth in the full year and the quarter, with
strong growth in Trelegy,
Augmentin and dermatology
products, partially offset by a decrease in other general medicine
products.
Footnote:
(1) Single inhaler triple
therapy
|
|
|
Financial
performance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Results
|
2024
|
|
Q4 2024
|
||||||||
|
|
£m
|
|
%
AER
|
|
%
CER
|
|
£m
|
|
%
AER
|
|
%
CER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
31,376
|
|
3
|
|
7
|
|
8,117
|
|
1
|
|
4
|
|
Cost of
sales
|
(9,048)
|
|
6
|
|
8
|
|
(2,559)
|
|
6
|
|
8
|
|
Selling,
general and administration
|
(11,015)
|
|
17
|
|
20
|
|
(2,663)
|
|
(1)
|
|
–
|
|
Research
and development
|
(6,401)
|
|
3
|
|
5
|
|
(2,031)
|
|
(1)
|
|
1
|
|
Royalty
income
|
639
|
|
(33)
|
|
(33)
|
|
176
|
|
(25)
|
|
(23)
|
|
Other
operating income/(expense)
|
(1,530)
|
|
|
|
|
|
(344)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
4,021
|
|
(40)
|
|
(33)
|
|
696
|
|
21
|
|
54
|
|
Net
finance expense
|
(547)
|
|
(19)
|
|
(18)
|
|
(139)
|
|
(28)
|
|
(27)
|
|
Share
of after tax profit/(loss) of associates
and joint ventures
|
(3)
|
|
|
|
|
|
–
|
|
|
|
|
|
Profit/(loss)
on disposal of interest in
associates
|
6
|
|
|
|
|
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
3,477
|
|
(43)
|
|
(34)
|
|
563
|
|
49
|
|
97
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(526)
|
|
|
|
|
|
(62)
|
|
|
|
|
|
Tax rate %
|
15.1%
|
|
|
|
|
|
11.0%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
2,951
|
|
(44)
|
|
(36)
|
|
501
|
|
26
|
|
65
|
|
Profit
attributable to non-controlling interests
|
376
|
|
|
|
|
|
87
|
|
|
|
|
|
Profit/(loss)
attributable to shareholders
|
2,575
|
|
|
|
|
|
414
|
|
|
|
|
|
|
2,951
|
|
(44)
|
|
(36)
|
|
501
|
|
26
|
|
65
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share
|
63.2p
|
|
(48)
|
|
(40)
|
|
10.1p
|
|
18
|
|
60
|
|
Financial Performance – Q4 2024
results unless otherwise stated, growth % and commentary at
CER.
|
|||||||||||
|
|
|
Core results
Reconciliations
between Total results and Core results for Full Year 2024, Full
Year 2023, Q4 2024 and Q4 2023 are set out on pages 19, 20, 22 and
23.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
Q4 2024
|
||||||||
|
|
£m
|
|
%
AER
|
|
%
CER
|
|
£m
|
|
%
AER
|
|
%
CER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
31,376
|
|
3
|
|
7
|
|
8,117
|
|
1
|
|
4
|
|
Cost of
sales
|
(7,870)
|
|
2
|
|
4
|
|
(2,339)
|
|
8
|
|
11
|
|
Selling,
general and administration
|
(8,974)
|
|
(1)
|
|
2
|
|
(2,702)
|
|
4
|
|
6
|
|
Research
and development
|
(6,023)
|
|
5
|
|
7
|
|
(1,821)
|
|
2
|
|
4
|
|
Royalty
income
|
639
|
|
(33)
|
|
(33)
|
|
176
|
|
(25)
|
|
(23)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Core
operating profit
|
9,148
|
|
4
|
|
11
|
|
1,431
|
|
(18)
|
|
(10)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Core
profit before taxation
|
8,613
|
|
6
|
|
13
|
|
1,293
|
|
(17)
|
|
(8)
|
|
Taxation
|
(1,462)
|
|
16
|
|
24
|
|
(174)
|
|
(26)
|
|
(17)
|
|
Tax rate %
|
17.0%
|
|
|
|
|
|
13.5%
|
|
|
|
|
|
Core
profit after taxation
|
7,151
|
|
4
|
|
11
|
|
1,119
|
|
(16)
|
|
(6)
|
|
Core
profit attributable to non-controlling
interests
|
654
|
|
|
|
|
|
173
|
|
|
|
|
|
Core
profit attributable to shareholders
|
6,497
|
|
|
|
|
|
946
|
|
|
|
|
|
|
7,151
|
|
4
|
|
11
|
|
1,119
|
|
(16)
|
|
(6)
|
|
Core
Earnings per share
|
159.3p
|
|
3
|
|
10
|
|
23.2p
|
|
(20)
|
|
(10)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
Q4 2024
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Cost of
sales
|
Total
|
9,048
|
6%
|
8%
|
|
2,559
|
6%
|
8%
|
|
% of sales
|
28.8%
|
0.6%
|
0.2%
|
|
31.5%
|
1.5%
|
1.1%
|
|
|
Core
|
7,870
|
2%
|
4%
|
|
2,339
|
8%
|
11%
|
|
|
% of sales
|
25.1%
|
(0.4%)
|
(0.7%)
|
|
28.8%
|
2.0%
|
1.7%
|
|
Full year 2024 Total and Core cost of sales as a percentage of
sales benefited from price and channel mix benefits, as well as
ongoing mix benefits in higher margin Specialty Medicines products,
and supply chain efficiencies. These benefits were offset in the
year and more than offset in the quarter by charges of
£150 million to drive
future supply chain efficiencies. Full year Total cost of sales
also increased due to additional amortisation for
Zejula
and Jemperli.
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
Q4 2024
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Selling,
general & administration
|
Total
|
11,015
|
17%
|
20%
|
|
2,663
|
(1%)
|
–%
|
|
% of sales
|
35.1%
|
4.2%
|
3.8%
|
|
32.8%
|
(0.5%)
|
(1.5%)
|
|
|
Core
|
8,974
|
(1%)
|
2%
|
|
2,702
|
4%
|
6%
|
|
|
% of sales
|
28.6%
|
(1.2%)
|
(1.3%)
|
|
33.3%
|
1.1%
|
0.5%
|
|
Total
SG&A growth in the full year was primarily driven by the
increase in Significant legal costs reflecting the charge of
£1.8 billion ($2.3 billion) in Q3 2024 in relation to
Zantac for the State Courts
Settlement, the Qui Tam
Settlement, and the remaining 7% of pending state court product
liability cases, partially offset by reduced future legal costs.
Since that time, the vast majority of the remaining state court
cases have been resolved or been dismissed such that less than 1%
of the state court cases remain (see details on page 35). In the
quarter, Total SG&A spend was in line with Q4
2023.
Core
SG&A growth in the full year was driven by continued
disciplined investment to support global market expansion and
disease awareness for key assets including Arexvy, Nucala, Shingrix and
Jemperli, and investment
behind long-acting HIV medicines, with the phasing of this
investment weighted more in Q4 2024. 2024 growth was partly offset
by a 1 percentage point favourable impact of the reversal of the
legal provision taken in Q1 2023 for the Zejula royalty dispute, following a
successful appeal.
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
Q4 2024
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Research
&
development
|
Total
|
6,401
|
3%
|
5%
|
|
2,031
|
(1%)
|
1%
|
|
% of sales
|
20.4%
|
(0.1%)
|
(0.4%)
|
|
25.0%
|
(0.4%)
|
(0.8%)
|
|
|
Core
|
6,023
|
5%
|
7%
|
|
1,821
|
2%
|
4%
|
|
|
% of sales
|
19.2%
|
0.2%
|
–%
|
|
22.4%
|
0.3%
|
–%
|
|
Total
R&D growth in the full year and the quarter was driven by an
increase in Core R&D investment, partly offset by lower
impairment charges compared with the full year 2023 and Q4
2023.
Core
R&D investment increased in the full year and the quarter
driven by progression across the portfolio.
In
Specialty Medicines, investment increased in Respiratory,
Immunology and Inflammation to support late-stage clinical
development programmes for camlipixant (refractory chronic cough),
the long acting TSLP asset acquired from the Aiolos Bio, Inc.
(Aiolos) acquisition, bepirovirsen (chronic hepatitis B) and
Benlysta (autoimmune
diseases), with ongoing strong investment in depemokimab (asthma
and eosinophilic inflammation).
In
Oncology, increased investment reflected acceleration on
antibody-drug-conjugates (ADCs) including those acquired from
Hansoh Pharma at the end of 2023, and studies into Blenrep (multiple myeloma) and
Jemperli (endometrial
cancer). In HIV investment increased on next-generation long-acting
treatment and preventative medicines.
In
Vaccines, clinical trial programmes associated with the
pneumococcal Multi Antigen Presenting System (MAPS) and mRNA
continued to drive investment.
These
increases were partly offset by reductions following the launches
of Arexvy and Ojjaara, and progression to completion
of gepotidacin and Zejula
studies.
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
Q4 2024
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Royalty
income
|
Total
|
639
|
(33%)
|
(33%)
|
|
176
|
(25%)
|
(23%)
|
|
|
Core
|
639
|
(33%)
|
(33%)
|
|
176
|
(25%)
|
(23%)
|
The
decrease in Total and Core royalty income in the full year and Q4
2024 primarily reflected the cessation of the majority of Gardasil
royalties at the end of 2023, with 2024 Gardasil royalties of
£42 million (2023: £472 million).
This
was partly offset by increases in Kesimpta and Biktarvy
royalties.
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
Q4 2024
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Other
operating
income/(expense)
|
Total
|
(1,530)
|
>(100%)
|
>(100%)
|
|
(344)
|
40%
|
40%
|
The
full year other operating expense reflected a charge of £1,839
million (2023: £546 million) principally arising from the
remeasurement of contingent consideration liabilities (CCL). This
primarily reflected improved longer term HIV prospects as well as
smaller foreign currency movements compared to 2023 and an increase
in liability for the Vaccines CCL. This was partly offset by higher
other net income of £287 million (2023: £200 million) as
well as a fair value gain of £22 million (2023: £17
million loss) on the retained stake in Haleon plc
(Haleon).
In Q4
2024 the other operating expense reflected a charge of £417
million (Q4 2023: £430 million) principally arising from CCL
remeasurements primarily reflecting foreign currency movements. In
the quarter, there were no fair value movements recorded for Haleon
shares (Q4 2023: £172 million loss) following the sale of the
remaining shares in May 2024. Other net income was higher compared
to the same period last year at £73 million (Q4 2023: £31
million).
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
Q4 2024
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Operating
profit
|
Total
|
4,021
|
(40%)
|
(33%)
|
|
696
|
21%
|
54%
|
|
|
% of sales
|
12.8%
|
(9.4%)
|
(8.3%)
|
|
8.6%
|
1.5%
|
3.4%
|
|
|
Core
|
9,148
|
4%
|
11%
|
|
1,431
|
(18%)
|
(10%)
|
|
|
% of sales
|
29.2%
|
0.2%
|
0.9%
|
|
17.6%
|
(4.1%)
|
(2.9%)
|
Total
operating profit margin was lower in the full year primarily due to
the charge of £1.8 billion ($2.3 billion) for the Zantac settlement, higher CCL charges
driven by improved longer term HIV prospects and other
remeasurements as well as unfavourable foreign currency movements,
additional amortisation for Zejula and Jemperli, and minimal movements on
Haleon shares (2023 fair value loss). Total operating profit margin
was higher in the quarter mainly due to no fair value movements on
Haleon shares (Q4 2023 fair value loss) and higher other net
income.
Core
operating profit growth in the full year benefited from strong
Specialty Medicines sales performance, with favourable product and
regional mix. This was partly offset by increased investment in
R&D and growth assets, and lower royalty income. 2024 also
includes a favourable impact from the reversal of the legal
provision taken in Q1 2023 for the Zejula royalty dispute, following a
successful appeal.
Lower
Core operating profit in the quarter primarily reflected charges to
drive future supply chain efficiencies, and increased investment in
R&D and growth assets as well as lower royalty income. The
adverse impact of lower sales of COVID-19 solutions had a two
percentage points impact in the full year on Core operating profit
growth and a 0.4 percentage point impact on Core operating profit
margin. There was minimal impact in the quarter.
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
Q4 2024
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Net
finance expense
|
Total
|
547
|
(19%)
|
(18%)
|
|
139
|
(28%)
|
(27%)
|
|
|
Core
|
532
|
(20%)
|
(19%)
|
|
138
|
(28%)
|
(27%)
|
The
decrease in net finance costs in the full year and Q4 2024 was
mainly driven by lower interest on short-term financing as a result
of cash received from the disposal of all Haleon shares, savings
from maturing bonds, and higher interest income on cash, partly
offset by fair value movements on net investment hedges. The full
year comparator to 2023 also benefitted from the net cost of bond
buybacks completed in Q1 2023.
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
Q4 2024
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Taxation
|
Total
|
526
|
(30%)
|
(19%)
|
|
62
|
>100
|
>100
|
|
|
Tax rate %
|
15.1%
|
|
|
|
11.0%
|
|
|
|
|
Core
|
1,462
|
16%
|
24%
|
|
174
|
(26%)
|
(17%)
|
|
|
Tax rate %
|
17.0%
|
|
|
|
13.5%
|
|
|
The
effective tax rate on Total results reflected the different tax
effects of the various Adjusting items included in Total results,
including the impact of the Zantac settlement.
The
effective tax rate on Core profits was in line with expectations
for the year and included the impact of new global minimum
corporate income tax rules which came into effect from 1 January
2024 in line with the OECD’s 'Pillar 2' model framework.
Issues related to taxation are described in Note 14,
‘Taxation’ in the Annual Report 2023. The Group
continues to believe it has made adequate provision for the
liabilities likely to arise from periods that are open and not yet
agreed by relevant tax authorities. The ultimate liability for such
matters may vary from the amounts provided and is dependent upon
the outcome of agreements with relevant tax
authorities.
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
Q4 2024
|
||||
|
|
|
£m
|
AER
|
CER
|
|
£m
|
AER
|
CER
|
|
Non-controlling
interests
("NCIs")
|
Total
|
376
|
(1%)
|
8%
|
|
87
|
81%
|
>100%
|
|
Core
|
654
|
14%
|
20%
|
|
173
|
14%
|
20%
|
|
The
increase in the full year Total NCIs at CER was driven by higher
ViiV Healthcare Total profits (partly offset by a higher
remeasurement loss on the CCL) as well as higher net profits in
some of the Group's other entities. ViiV Healthcare Total profits
were lower at AER, reflecting adverse currency impacts, with an
allocation of £356 million (2023: £374
million).
The
increase in Total NCIs in the quarter was primarily driven by
higher ViiV Healthcare profits including a lower remeasurement loss
on the CCL, and higher net profits in some of the Group's other
entities.
The
increase in Core NCIs in the full year and Q4 2024 primarily
reflected higher core profit allocations from ViiV Healthcare, with
£634 million in 2024 (2023: £566 million) and £171
million in Q4 2024 (Q4 2023: £154 million), as well as higher
net profits in some of the Group’s other entities with
NCIs.
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
Q4 2024
|
||||
|
|
|
£p
|
AER
|
CER
|
|
£p
|
AER
|
CER
|
|
Earnings
per share
|
Total
|
63.2p
|
(48%)
|
(40%)
|
|
10.1p
|
18%
|
60%
|
|
Core
|
159.3p
|
3%
|
10%
|
|
23.2p
|
(20%)
|
(10%)
|
|
The
decrease in the full year Total EPS was primarily due to a charge
of £1.8 billion ($2.3 billion) for the Zantac settlement (see details on page
35) and higher CCL charges. The increase in the Q4 2024 Total EPS
is driven by no fair value movements on Haleon shares compared to a
fair value loss of £172 million in Q4 2023.
The
increase in the Core EPS in the full year primarily reflected the
growth in Core operating profit as well as lower finance costs,
partly offset by a higher effective taxation rate and higher
non-controlling interests. The decrease in the Q4 2024 Core EPS is
driven by lower Core operating profit and higher non-controlling
interests, partly offset by lower finance costs and a lower
effective taxation rate. Lower sales of COVID-19 solutions reduced
Core EPS by two percentage points in the full year.
Currency impact on results
The
results for the year 2024 are based on average exchange rates,
principally US$1.28/£1, €1.18/£1 and
Yen193/£1. The results for Q4 2024 are based on average
exchange rates, principally $1.27/£1, €1.20/£1 and
Yen195/£1. The period-end exchange rates were $1.25/£1,
€1.20/£1 and Yen197/£1. Comparative exchange rates
are given on page 37.
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
Q4 2024
|
||||
|
|
|
£m/£p
|
AER
|
CER
|
|
£m/£p
|
AER
|
CER
|
|
Turnover
|
|
31,376
|
3%
|
7%
|
|
8,117
|
1%
|
4%
|
|
Earnings
per share
|
Total
|
63.2p
|
(48%)
|
(40%)
|
|
10.1p
|
18%
|
60%
|
|
Core
|
159.3p
|
3%
|
10%
|
|
23.2p
|
(20%)
|
(10%)
|
|
In the
full year and Q4 2024, the adverse currency impact primarily
reflected the strengthening of Sterling against the US Dollar,
Euro, Yen and emerging market currencies. Exchange gains or losses
on the settlement of intercompany transactions had a negligible
impact on Total and Core EPS in the full year, and in the quarter
the impact was eight percentage points on Total EPS and three
percentage points on Core EPS.
|
|
|
Cash generation
|
|
|
|
|
|
|
|
|
|
|
Cash flow
|
|||||||
|
|
2024
£m
|
|
2023
£m
|
|
Q4 2024
£m
|
|
Q4
2023
£m
|
|
Cash
generated from operations (£m)
|
7,861
|
|
8,096
|
|
2,586
|
|
3,681
|
|
Net
cash generated from operating activities (£m)
|
6,554
|
|
6,768
|
|
2,329
|
|
3,196
|
|
Free
cash inflow/(outflow)* (£m)
|
2,863
|
|
3,409
|
|
924
|
|
2,095
|
|
Free
cash flow growth (%)
|
(16)%
|
|
2%
|
|
(56%)
|
|
>100%
|
|
Free
cash flow conversion* (%)
|
>100%
|
|
69%
|
|
>100%
|
|
>100%
|
|
Total
net debt** (£m)
|
13,095
|
|
15,040
|
|
13,095
|
|
15,040
|
|
*
|
Free cash flow and free cash flow
conversion are defined on page 50. Free cash flow is analysed on
page 40.
|
|
**
|
Net debt is analysed on page
40.
|
2024
Cash generated from operating activities was £7,861 million
(2023: £8,096 million) and excluding £672
million payments for the
Zantac
settlement was £8,533
million. The increase
excluding Zantac reflected higher Core operating profit, the
benefit of Q4 2023 Arexvy receivables' collections in Q1 2024, and lower
pension contributions, partly offset by the timing impact from
lower returns and rebates, including the impact of the removal of
the AMP cap, and lower receivables at the end of the
year.
Total
contingent consideration cash payments in 2024 were
£1,254 million (2023: £1,145 million).
£1,235 million (2023: £1,134 million) of these
were recognised in cash flows from operating activities, including
cash payments made to Shionogi & Co. Ltd (Shionogi) of
£1,190 million (2023:
£1,106 million).
Free cash inflow was £2,863 million for 2024 (2023:
£3,409 million) and excluding payments for the
Zantac
settlement was £3,535
million. The increase
excluding Zantac was primarily driven by higher cash generated
from operating activities as well as lower net interest paid,
partly offset by higher capital expenditure on intangible assets
including the £342 million upfront payment to CureVac
N.V.
Q4 2024
Cash generated from operations for the quarter was £2,586
million (Q4 2023: £3,681 million). The decrease primarily
reflected £672 million payments related to the
Zantac
settlement (£3,258
million excluding Zantac settlement payments).
Total
contingent consideration cash payments in the quarter were
£319 million (Q4 2023: £285 million).
£311 million (Q4 2023: £281 million) of
these were recognised in cash flows from operating activities,
including cash payments made to Shionogi of
£290 million (Q4 2023:
£272 million).
Free cash inflow was £924 million for the quarter (Q4 2023:
£2,095 million) and excluding payments for the
Zantac
settlement was £1,596
million. The decrease is driven by
lower cash generated from operations and higher capital expenditure
on intangible assets and property, plant and equipment, partly
offset by lower tax payments.
Total Net debt
At 31
December 2024, net debt was £13,095 million, compared with
£15,040 million at 31 December 2023, comprising gross debt of
£16,986 million and cash and liquid investments of £3,891
million. See net debt information on page 40.
Net
debt decreased by £1,945 million primarily due to £2,863
million of free cash inflow and £2,356 million proceeds from
the disposal of investments, primarily due to the sale of the
remaining retained stake in Haleon. This was partly offset by the
net acquisition costs of Aiolos and Elsie Biotechnologies of
£805 million, and dividends paid to shareholders of
£2,444 million.
At 31
December 2024, GSK had short-term borrowings (including overdrafts
and lease liabilities) repayable within 12 months of £2,349
million and £1,411 million repayable in the subsequent
year.
|
|
|
|
|
Page
|
|
Q4 2024
pipeline highlights
|
13
|
|
Responsible
business
|
15
|
|
Total
and Core results
|
17
|
|
Income
statement
|
25
|
|
Statement
of comprehensive income
|
26
|
|
Balance
sheet
|
27
|
|
Statement
of changes in equity
|
28
|
|
Cash
flow statement
|
29
|
|
Sales
tables
|
30
|
|
Segment
information
|
33
|
|
Legal
matters
|
35
|
|
Returns
to shareholders
|
36
|
|
Additional
information
|
37
|
|
Net
debt information
|
40
|
|
Post
balance sheet event
|
41
|
|
Related
party transactions
|
41
|
|
R&D
commentary
|
42
|
|
Reporting
definitions
|
50
|
|
Guidance
and outlooks, assumptions and cautionary statements
|
52
|
|
Contacts
|
|
GSK plc
(LSE/NYSE:GSK) is a global biopharma company with a purpose to
unite science, technology, and talent to get ahead of disease
together. Find out more at www.gsk.com.
|
|
|
|
|
|
|
|
GSK enquiries:
|
|
|
|
|
|
Media
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington)
|
|
|
|
|
|
|
|
|
Investor
Relations
|
Annabel
Brownrigg-Gleeson
|
+44 (0)
7901 101944
|
(London)
|
|
|
|
James
Dodwell
|
+44 (0)
7881 269066
|
(London)
|
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
|
Jeff
McLaughlin
|
+1 215
589 3774
|
(Philadelphia)
|
|
|
|
|
|
|
|
|
Registered in England & Wales:
No.
3888792
|
||||
|
|
||||
|
Registered Office:
79 New
Oxford Street
London,
WC1A
1DG
|
||||
|
|
|
|||
|
Q4 2024 pipeline highlights (since
30 October 2024)
|
|
|||
|
|
|
|
|
|
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
Regulatory approvals or other regulatory actions
|
Nucala
|
Chronic
rhinosinusitis with nasal polyps
|
Regulatory
approval (CN)
|
|
Jemperli
|
RUBY
part 1 (OS overall population, 1L endometrial cancer)
|
Regulatory
approval (EU)
|
|
|
Vokabria + Rekambys
|
HIV
infection, adolescents
|
Regulatory
approval (EU)
|
|
|
Arexvy
|
RSV,
adults aged 50-59 years at increased risk
|
Regulatory
approval (JP)
|
|
|
Menveo
|
Liquid
formulation, meningitis ACWY
|
Regulatory
approval (EU)
|
|
|
Regulatory submissions or acceptances
|
depemokimab
|
ANCHOR-1/2
(chronic rhinosinusitis with nasal polyps
|
Regulatory
acceptance
(EU,
JP, CN)
|
|
depemokimab
|
SWIFT-1/2
(severe asthma)
|
Regulatory
acceptance
(EU,
JP, CN)
|
|
|
Nucala
|
MATINEE
(chronic obstructive pulmonary disease)
|
Regulatory
acceptance (US)
|
|
|
Blenrep
|
DREAMM-7/8
(2L+ multiple myeloma)
|
Regulatory
acceptance (US)
|
|
|
Blenrep
|
DREAMM-7
(2L+ multiple myeloma)
|
Regulatory
acceptance (CN) with Priority Review
|
|
|
Shingrix
|
Liquid
formulation, shingles
|
Regulatory
acceptance
(US,
EU)
|
|
|
Phase III data readouts or other significant events
|
Blenrep
|
DREAMM-7
(2L+ multiple myeloma)
|
Further
positive phase III data readout
|
|
linerixibat
|
GLISTEN
(cholestatic pruritus in primary biliary cholangitis)
|
Positive
phase III data reported
|
|
|
Zejula
|
FIRST
(1L maintenance ovarian cancer)
|
Positive
phase III data readout
|
|
|
Regulatory designations and other significant events
|
Jemperli
|
Locally
advanced dMMR/MSI-H rectal cancer
|
Breakthrough
Designation (US)
|
|
GSK5764227
(B7-H3-targeted antibody-drug conjugate)
|
Extensive-stage
small-cell lung cancer
|
Priority
Medicines (PRIME) granted (EU)
|
|
|
GSK5764227
(B7-H3-targeted antibody-drug conjugate)
|
Relapsed
or refractory osteosarcoma
|
Breakthrough
Designation (US)
|
|
|
|
|
|
|
|
Anticipated news flow
|
|
|
|
|
|
|
Timing
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
H1 2025
|
depemokimab
|
SWIFT-1/2
(severe asthma)
|
Regulatory
submission (US)
|
|
depemokimab
|
ANCHOR-1/2
(chronic rhinosinusitis with nasal polyps)
|
Regulatory
submission (US)
|
|
|
depemokimab
|
AGILE
(severe asthma)
|
Phase
III data readout
|
|
|
linerixibat
|
GLISTEN
(cholestatic pruritus in primary biliary cholangitis)
|
Regulatory
submission
(US,
EU, CN)
|
|
|
Nucala
|
MATINEE
(chronic obstructive pulmonary disease)
|
Regulatory
decision (US)
|
|
|
Nucala
|
MATINEE
(chronic obstructive pulmonary disease)
|
Regulatory
submission
(CN,
EU)
|
|
|
Blenrep
|
DREAMM-7/8
(2L+ multiple myeloma)
|
Regulatory
decision (JP)
|
|
|
cobolimab
|
COSTAR
(non-small cell lung cancer)
|
Phase
III data readout
|
|
|
Zejula
|
ZEAL
(1L maintenance non-small cell lung cancer)
|
Phase
III data readout
|
|
|
gepotidacin
|
EAGLE-2/3
(uncomplicated urinary tract infection)
|
Regulatory
decision (US)
|
|
|
gepotidacin
|
EAGLE-1
(urogenital gonorrhoea)
|
Regulatory
submission (US)
|
|
|
MenABCWY
(gen 1) vaccine candidate
|
Meningococcal
ABCWY
|
Regulatory
decision (US)
|
|
|
Shingrix
|
Shingles,
adults aged 18+ years
|
Regulatory
decision (CN)
|
|
|
Shingrix
|
Shingles,
liquid formulation
|
Regulatory
decision (US)
|
|
Anticipated news flow continued
|
|
|
|
|
|
|
Timing
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
H2 2025
|
camlipixant
|
CALM-1/2
(refractory chronic cough)
|
Phase
III data readout
|
|
depemokimab
|
SWIFT-1/2
(severe asthma)
|
Regulatory
decision (US)
|
|
|
depemokimab
|
ANCHOR-1/2
(chronic rhinosinusitis with nasal polyps)
|
Regulatory
decision (US)
|
|
|
depemokimab
|
NIMBLE
(asthma)
|
Phase
III data readout
|
|
|
linerixibat
|
GLISTEN
(cholestatic pruritus in primary biliary cholangitis)
|
Regulatory
decision (US)
|
|
|
linerixibat
|
GLISTEN
(cholestatic pruritus in primary biliary cholangitis)
|
Regulatory
submission (JP)
|
|
|
Ventolin
|
Low
carbon MDI (asthma)
|
Phase
III data readout
|
|
|
Ventolin
|
Low
carbon MDI (asthma)
|
Regulatory
submission (EU)
|
|
|
Blenrep
|
DREAMM-7/8
(2L+ multiple myeloma)
|
Regulatory
decision (US, EU)
|
|
|
Blenrep
|
DREAMM-8
(2L + multiple myeloma)
|
Regulatory
submission (CN)
|
|
|
cobolimab
|
COSTAR,
(2L non-small cell lung cancer)
|
Regulatory
submission
(US,
EU)
|
|
|
Arexvy
|
RSV,
adults aged 18-49 years at increased risk, 18+
immunocompromised
|
Regulatory
submission
(US,
EU, JP)
|
|
|
Bexsero
|
Meningococcal
B (infants)
|
Phase
III data read out
|
|
|
Bexsero
|
Meningococcal
B (infants)
|
Regulatory
submission (US)
|
|
|
gepotidacin
|
EAGLE-1
(urogenital gonorrhoea)
|
Regulatory
decision (US)
|
|
|
tebipenem
pivoxil
|
PIVOT-PO
(complicated urinary tract infection)
|
Phase
III data readout
|
|
|
tebipenem
pivoxil
|
PIVOT-PO
(complicated urinary tract infection)
|
Regulatory
submission (US)
|
|
|
2026
|
camlipixant
|
CALM-1/2
(refractory chronic cough)
|
Phase
III data read out
|
|
camlipixant
|
CALM-1/2
(refractory chronic cough)
|
Regulatory
submission
(US,
EU)
|
|
|
depemokimab
|
OCEAN
(Eosinophilic granulomatosis with polyangiitis)
|
Phase
III data read out
|
|
|
depemokimab
|
OCEAN
(Eosinophilic granulomatosis with polyangiitis)
|
Regulatory
submission
(US,
EU, CN, JP)
|
|
|
depemokimab
|
SWIFT-1/2
(severe asthma)
|
Regulatory
decision
(EU,
CN, JP)
|
|
|
depemokimab
|
ANCHOR-1/2
(chronic rhinosinusitis with nasal polyps)
|
Regulatory
decision
(EU,
CN, JP)
|
|
|
latozinemab
|
INFRONT-3
(frontotemporal dementia)
|
Phase
III data read out
|
|
|
latozinemab
|
INFRONT-3
(frontotemporal dementia)
|
Regulatory
submission
(US,
EU)
|
|
|
linerixibat
|
GLISTEN
(cholestatic pruritus in primary biliary cholangitis)
|
Regulatory
decision
(EU,
CN, JP)
|
|
|
Nucala
|
MATINEE
(chronic obstructive pulmonary disease)
|
Regulatory
decision (EU, CN)
|
|
|
Ventolin
|
Low
carbon MDI (asthma)
|
Regulatory
decision (EU)
|
|
|
Blenrep
|
DREAMM-7/8
(2L+ multiple myeloma)
|
Regulatory
decision (CN)
|
|
|
cobolimab
|
COSTAR
(2L non-small cell lung cancer)
|
Regulatory
decision (US, EU)
|
|
|
Jemperli
|
AZUR-1
(rectal cancer)
|
Phase
II (pivotal) data read out
|
|
|
cabotegravir
|
Q4M
PrEP (HIV)
|
Phase
II (pivotal) data read out
|
|
|
cabotegravir
|
Q4M
PrEP (HIV)
|
Regulatory
submission (US)
|
|
|
cabotegravir
|
Q4M
PrEP (HIV)
|
Regulatory
decision (US)
|
|
|
Arexvy
|
RSV,
adults aged 18-49 years at increased risk and 18+
immunocompromised
|
Regulatory
decision
(US,
EU, JP)
|
|
|
bepirovirsen
|
B-WELL
1/2 (hepatitis B virus)
|
Phase
III data read out
|
|
|
bepirovirsen
|
B-WELL
1/2 (hepatitis B virus)
|
Regulatory
submission
(US,
EU, CN, JP)
|
|
|
bepirovirsen
|
B-WELL
1/2 (hepatitis B virus)
|
Regulatory
decision (US, JP)
|
|
|
Bexsero
|
Meningococcal
B (infants)
|
Regulatory
decision (US)
|
|
|
tebipenem
pivoxil
|
PIVOT-PO
(complicated urinary tract infection)
|
Regulatory
decision (US)
|
|
Refer to pages
42 to 49 for further details on several key medicines and
vaccines in development by therapy area.
|
Trust: progress in 2024 on our six
priority areas for responsible business
Building Trust by operating responsibly is integral to GSK’s
strategy and culture. This will support growth and returns to
shareholders, reduce risk, and help GSK’s people thrive while
delivering sustainable health impact at scale. The Company has
previously identified six areas that address what is most material
to GSK’s business and the issues that matter the most to its
stakeholders. Highlights below include activity since Q3 2024
results. For more details on annual updates, please see
GSK's ESG Performance Report 2023(1).
GSK
remains committed to abiding by the laws in all jurisdictions in
which we operate, including anti-discrimination laws. We make
changes as necessary as law and policy evolves.
Access
Commitment:
to make GSK’s vaccines and
medicines available at value-based prices that are sustainable for
the business and implement access strategies that increase the use
of GSK’s vaccines and medicines to treat and protect
underserved people.
Progress
since Q3 2024:
|
|
|
|
●
|
GSK
ranked second in the ninth iteration of the Access to Medicine
Index (ATMI), as one of two leading companies. This means GSK has
placed first or second in the Index since its inception in 2008.
The Index is an independent, investor-backed report that ranks 20
of the world’s largest pharmaceutical companies on progress
to improve access at scale in 113 lower income countries and
focuses on 81 high burden priority diseases. GSK continues to show
strong leadership in its Access to Medicines Index
ranking(2)
|
|
●
|
In
December, GSK and long-term partner Medicines for Malaria Venture
(MMV), announced that the World Health Organisation (WHO) has
awarded prequalification to tafenoquine, the first single-dose
medicine for the prevention of relapse of Plasmodium
vivax (P. vivax) malaria. Tafenoquine, co-administered with
chloroquine, is now also included in WHO’s updated Guidelines
for malaria, in South America, marking the first time the medicine
has been recommended by WHO. This milestone is a significant step
toward closing the treatment gap for P. vivax malaria. The WHO
prequalification and updated guidelines include both adults and
children aged 2 years and older, weighing at least 10 kg. First
single-dose medicine for P. vivax malaria prequalified by WHO and
included in WHO Guidelines(3).
|
Global health and health security
Commitment:
develop novel products and technologies to treat and prevent
priority diseases, including pandemic threats.
|
|
|
|
●
|
Performance
metrics related to global health and health security are updated
annually in GSK's 2023 Report(1) on page
15.
|
Environment
Commitment:
committed to a net zero, nature-positive, healthier planet with
ambitious goals set for 2030 and 2045.
Progress
since Q3 2024:
|
|
|
|
●
|
In
October, GSK was one of the first companies to announce the
adoption of Science Based Targets for Nature, with our validated
Freshwater target focused on our direct operations in the
water-stressed Upper Godavari basin in India.
|
|
●
|
Performance
metrics related to environment are updated annually with related
details in GSK's 2023 Report(1) on page
18.
|
Inclusion and diversity
Commitment:
create an inclusive workplace through equal employment opportunity
and non-discrimination; reflect patients impacted by the disease
under study in our clinical trials; and support future talent in
STEM regardless of background.
|
|
|
|
●
|
Performance
metrics related to these matters are updated annually with related
details in GSK's 2023 Report(1) on page
26.
|
Ethical standards
Commitment:
promote ethical behaviour across GSK’s business by supporting
its employees to do the right thing and working with suppliers that
share GSK’s standards and operate responsibly.
|
|
|
|
●
|
Performance
metrics related to ethical standards are updated annually with
related details in GSK's 2023 Report(1) on page
30.
|
Product governance
Commitment:
maintain robust quality and safety processes and responsibly use
data and new technologies.
|
|
|
|
●
|
Performance
metrics related to product governance are updated annually with
related details in GSK's 2023 Report(1) on page
35.
|
External benchmarking
|
|
|
|
|
|
External benchmark
|
Current
score/ranking
|
Previous
score/ranking
|
Comments
|
|
S&P
Global’s Corporate Sustainability Assessment
|
78
|
80
|
Current
score updated September 2024
|
|
Access
to Medicines Index(4)
|
3.72
|
4.06
|
Second
in the Index, updated bi-annually, current results from November
2024
|
|
Antimicrobial
resistance benchmark
|
84%
|
86%
|
Led the
benchmark since its inception in 2018; Current ranking updated
November 2021
|
|
CDP
Climate Change
|
A-
|
A-
|
Updated
annually, current scores updated February 2024 (for supplier
engagement, March 2023)
|
|
CDP
Water Security
|
A-
|
B
|
|
|
CDP
Forests (palm oil)
|
B
|
A-
|
|
|
CDP
Forests (timber)
|
B
|
B
|
|
|
CDP
supplier engagement rating
|
Leader
|
Leader
|
|
|
Sustainalytics
|
15.0
|
15.4
|
1st
percentile in pharma subindustry group; lower score represents
lower risk. Current score as at October 2024
|
|
MSCI
|
AA
|
AA
|
Last
rating action date: September 2023
|
|
Moody’s
ESG solutions
|
62
|
61
|
Current
score updated August 2023
|
|
ISS
Corporate Rating
|
B+
|
B+
|
Current
score updated October 2024
|
|
FTSE4Good
|
Member
|
Member
|
Member
since 2004, latest review in June 2024
|
|
ShareAction’s
Workforce Disclosure Initiative
|
79%
|
77%
|
Current
score updated January 2024
|
Footnotes:
|
(1)
|
https://www.gsk.com/media/11009/esg-performance-report-2023.pdf
|
|
(2)
|
https://www.gsk.com/en-gb/media/press-releases/statement-gsk-continues-to-show-strong-leadership-in-its-access-to-medicines-index-ranking/
|
|
(3)
|
https://www.gsk.com/en-gb/media/press-releases/first-single-dose-medicine-for-p-vivax-malaria-prequalified-by-who/
|
|
(4)
|
https://accesstomedicinefoundation.org/resource/2024-access-to-medicine-index
|
Total and Core
results
Total
reported results represent the Group’s overall
performance.
GSK
made one update to its reporting framework in Q1 2024 which was to
change the description of Adjusted results to Core to align with
European peers in the pharmaceutical industry but with no change to
the basis or figures. In Q2 2024 an update was made to the
definition of Core results to exclude amounts greater than £25
million from the foreign currency translation reserve which are
reclassified to the income statement upon the liquidation of a
subsidiary. There is no change to Total Results.
GSK
uses a number of non-IFRS measures to report the performance of its
business. Core results and other non-IFRS measures may be
considered in addition to, but not as a substitute for, or superior
to, information presented in accordance with IFRS. Core results are
defined below and other non-IFRS measures are defined on page
50.
GSK
believes that Core results, when considered together with Total
results, provide investors, analysts and other stakeholders with
helpful complementary information to understand better the
financial performance and position of the Group from period to
period, and allow the Group’s performance to be more easily
compared against the majority of its peer companies. These measures
are also used by management for planning and reporting purposes.
They may not be directly comparable with similarly described
measures used by other companies.
GSK
encourages investors and analysts not to rely on any single
financial measure but to review GSK’s quarterly results
announcements, including the financial statements and notes, in
their entirety.
GSK is
committed to continuously improving its financial reporting, in
line with evolving regulatory requirements and best practice. In
line with this practice, GSK expects to continue to review and
refine its reporting framework.
Core
results exclude the following items in relation to our operations
from Total results, together with the tax effects of all of these
items:
|
●
|
amortisation
of intangible assets (excluding computer software and capitalised
development costs)
|
|
●
|
impairment
of intangible assets (excluding computer software) and
goodwill
|
|
●
|
major
restructuring costs, which include impairments of tangible assets
and computer software, (under specific Board approved programmes
that are structural, of a significant scale and where the costs of
individual or related projects exceed £25 million), including
integration costs following material acquisitions
|
|
●
|
transaction-related
accounting or other adjustments related to significant
acquisitions
|
|
●
|
proceeds
and costs of disposal of associates, products and businesses;
significant settlement income; Significant legal charges (net of
insurance recoveries) and expenses on the settlement of litigation
and government investigations; other operating income other than
royalty income, and other items including amounts reclassified from
the foreign currency translation reserve to the income statement
upon the liquidation of a subsidiary where the amount exceeds
£25 million
|
Costs
for all other ordinary course smaller scale restructuring and legal
charges and expenses from operations are retained within both Total
and Core results.
As Core
results include the benefits of Major restructuring programmes but
exclude significant costs (such as Significant legal, major
restructuring and transaction items) they should not be regarded as
a complete picture of the Group’s financial performance,
which is presented in Total results. The exclusion of other
Adjusting items may result in Core earnings being materially higher
or lower than Total earnings. In particular, when significant
impairments, restructuring charges and legal costs are excluded,
Core earnings will be higher than Total earnings.
GSK has
undertaken a number of Major restructuring programmes in response
to significant changes in the Group’s trading environment or
overall strategy or following material acquisitions. Within the
Pharmaceuticals sector, the highly regulated manufacturing
operations and supply chains and long lifecycle of the business
mean that restructuring programmes, particularly those that involve
the rationalisation or closure of manufacturing or R&D sites
are likely to take several years to complete. Costs, both cash and
non-cash, of these programmes are provided for as individual
elements are approved and meet the accounting recognition criteria.
As a result, charges may be incurred over a number of years
following the initiation of a Major restructuring
programme.
Significant
legal charges and expenses are those arising from the settlement of
litigation or government investigations that are not in the normal
course and materially larger than more regularly occurring
individual matters. They also include certain major legacy
matters.
Reconciliations
between Total and Core results, providing further information on
the key Adjusting items, are set out on pages 19, 20, 22 and
23.
GSK
provides earnings guidance to the investor community on the basis
of Core results. This is in line with peer companies and
expectations of the investor community, supporting easier
comparison of the Group’s performance with its peers. GSK is
not able to give guidance for Total results as it cannot reliably
forecast certain material elements of the Total results,
particularly the future fair value movements on contingent
consideration and put options that can and have given rise to
significant adjustments driven by external factors such as currency
and other movements in capital markets.
ViiV Healthcare
ViiV
Healthcare is a subsidiary of the Group and 100% of its operating
results (turnover, operating profit, profit after tax) are included
within the Group income statement.
Earnings
are allocated to the three shareholders of ViiV Healthcare on the
basis of their respective equity shareholdings (GSK 78.3%, Pfizer
11.7% and Shionogi 10%) and their entitlement to preferential
dividends, which are determined by the performance of certain
products that each shareholder contributed. As the relative
performance of these products changes over time, the proportion of
the overall earnings allocated to each shareholder also changes. In
particular, the increasing proportion of sales of dolutegravir and
cabotegravir-containing products has a favourable impact on the
proportion of the preferential dividends that is allocated to GSK.
Adjusting items are allocated to shareholders based on their equity
interests. GSK was entitled to approximately 85% of the Total
earnings and 83% of the Core earnings of ViiV Healthcare for
2024.
As
consideration for the acquisition of Shionogi’s interest in
the former Shionogi-ViiV Healthcare joint venture in 2012, Shionogi
received the 10% equity stake in ViiV Healthcare and ViiV
Healthcare also agreed to pay additional future cash consideration
to Shionogi, contingent on the future sales performance of the
products being developed by that joint venture, dolutegravir and
cabotegravir. Under IFRS 3 ‘Business combinations’, GSK
was required to provide for the estimated fair value of this
contingent consideration at the time of acquisition and is required
to update the liability to the latest estimate of fair value at
each subsequent period end. The liability for the contingent
consideration recognised in the balance sheet at the date of
acquisition was £659 million. Subsequent remeasurements are
reflected within other operating income/(expense) and within
Adjusting items in the income statement in each
period.
Cash
payments to settle the contingent consideration are made to
Shionogi by ViiV Healthcare each quarter, based on the actual sales
performance and other income of the relevant products in the
previous quarter. These payments reduce the balance sheet liability
and hence are not recorded in the income statement. The cash
payments made to Shionogi by ViiV Healthcare in the year ended 31
December 2024 were £1,190 million.
As the
liability is required to be recorded at the fair value of estimated
future payments, there is a significant timing difference between
the charges that are recorded in the Total income statement to
reflect movements in the fair value of the liability and the actual
cash payments made to settle the liability.
Further
explanation of the acquisition-related arrangements with ViiV
Healthcare are set out on pages 84 and 85 of the Annual Report
2023.
Adjusting items
|
The
reconciliations between Total results and Core results for 2024 and
2023 are set out below.
Year
ended 31 December 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
results
£m
|
|
Intangible
amort-
isation
£m
|
|
Intangible
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Significant
legal,
Divest-
ments
and
other
items
£m
|
|
Core
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
31,376
|
|
|
|
|
|
|
|
|
|
|
|
31,376
|
|
Cost of
sales
|
(9,048)
|
|
947
|
|
|
|
163
|
|
40
|
|
28
|
|
(7,870)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
22,328
|
|
947
|
|
|
|
163
|
|
40
|
|
28
|
|
23,506
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(11,015)
|
|
|
|
|
|
160
|
|
2
|
|
1,879
|
|
(8,974)
|
|
Research
and development
|
(6,401)
|
|
55
|
|
314
|
|
9
|
|
|
|
|
|
(6,023)
|
|
Royalty
income
|
639
|
|
|
|
|
|
|
|
|
|
|
|
639
|
|
Other
operating income/(expense)
|
(1,530)
|
|
|
|
|
|
21
|
|
1,839
|
|
(330)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
4,021
|
|
1,002
|
|
314
|
|
353
|
|
1,881
|
|
1,577
|
|
9,148
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance expense
|
(547)
|
|
|
|
|
|
1
|
|
|
|
14
|
|
(532)
|
|
Share
of after tax profit/(loss) of associates and joint
venture
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
(3)
|
|
Profit/(loss)
on disposal of interests in associates and joint
ventures
|
6
|
|
|
|
|
|
|
|
|
|
(6)
|
|
–
|
|
Profit before taxation
|
3,477
|
|
1,002
|
|
314
|
|
354
|
|
1,881
|
|
1,585
|
|
8,613
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(526)
|
|
(208)
|
|
(63)
|
|
(80)
|
|
(311)
|
|
(274)
|
|
(1,462)
|
|
Tax rate %
|
15.1%
|
|
|
|
|
|
|
|
|
|
|
|
17.0%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
2,951
|
|
794
|
|
251
|
|
274
|
|
1,570
|
|
1,311
|
|
7,151
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to non-controlling interests
|
376
|
|
|
|
|
|
|
|
278
|
|
|
|
654
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit/(loss) attributable to shareholders
|
2,575
|
|
794
|
|
251
|
|
274
|
|
1,292
|
|
1,311
|
|
6,497
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,951
|
|
794
|
|
251
|
|
274
|
|
1,570
|
|
1,311
|
|
7,151
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
63.2p
|
|
19.5p
|
|
6.1p
|
|
6.7p
|
|
31.7p
|
|
32.1p
|
|
159.3p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares (millions)
|
4,077
|
|
|
|
|
|
|
|
|
|
|
|
4,077
|
|
|
|
Year ended 31 December 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
results
£m
|
|
Intangible
amort-
isation
£m
|
|
Intangible
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Significant
legal,
Divest-
ments
and
other
items
£m
|
|
Core
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
30,328
|
|
|
|
|
|
|
|
|
|
|
|
30,328
|
|
Cost of
sales
|
(8,565)
|
|
647
|
|
|
|
164
|
|
13
|
|
25
|
|
(7,716)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
21,763
|
|
647
|
|
|
|
164
|
|
13
|
|
25
|
|
22,612
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(9,385)
|
|
|
|
|
|
216
|
|
13
|
|
127
|
|
(9,029)
|
|
Research
and development
|
(6,223)
|
|
72
|
|
398
|
|
2
|
|
|
|
1
|
|
(5,750)
|
|
Royalty
income
|
953
|
|
|
|
|
|
|
|
|
|
|
|
953
|
|
Other
operating income/(expense)
|
(363)
|
|
|
|
|
|
|
|
546
|
|
(183)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
6,745
|
|
719
|
|
398
|
|
382
|
|
572
|
|
(30)
|
|
8,786
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance expense
|
(677)
|
|
|
|
|
|
1
|
|
|
|
7
|
|
(669)
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
(5)
|
|
|
|
|
|
|
|
|
|
|
|
(5)
|
|
Profit/(loss)
on disposal of interest in associates
|
1
|
|
|
|
|
|
|
|
|
|
(1)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
6,064
|
|
719
|
|
398
|
|
383
|
|
572
|
|
(24)
|
|
8,112
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(756)
|
|
(154)
|
|
(94)
|
|
(83)
|
|
(100)
|
|
(70)
|
|
(1,257)
|
|
Tax rate %
|
12.5%
|
|
|
|
|
|
|
|
|
|
|
|
15.5%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
5,308
|
|
565
|
|
304
|
|
300
|
|
472
|
|
(94)
|
|
6,855
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to non-controlling interests
|
380
|
|
|
|
|
|
|
|
192
|
|
|
|
572
|
|
Profit/(loss) attributable to shareholders
|
4,928
|
|
565
|
|
304
|
|
300
|
|
280
|
|
(94)
|
|
6,283
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,308
|
|
565
|
|
304
|
|
300
|
|
472
|
|
(94)
|
|
6,855
|
|
Earnings per share
|
121.6p
|
|
13.9p
|
|
7.5p
|
|
7.4p
|
|
6.9p
|
|
(2.2)p
|
|
155.1p
|
|
Weighted
average number of shares (millions)
|
4,052
|
|
|
|
|
|
|
|
|
|
|
|
4,052
|
Adjusting items full year
2024
Major restructuring and integration
|
Total
Major restructuring charges incurred in 2024 were £353 million
(2023: £382 million), analysed as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
2023
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Separation
restructuring programme
|
200
|
|
36
|
|
236
|
|
199
|
|
117
|
|
316
|
|
Significant
acquisitions
|
59
|
|
1
|
|
60
|
|
65
|
|
1
|
|
66
|
|
Legacy
programmes
|
48
|
|
9
|
|
57
|
|
(1)
|
|
1
|
|
-
|
|
|
307
|
|
46
|
|
353
|
|
263
|
|
119
|
|
382
|
The
Separation restructuring programme incurred cash charges of
£200 million primarily from the restructuring of some
commercial and administrative functions as well as Supply Chain.
The non-cash charges of £36 million primarily reflected the
write-down of assets in manufacturing locations.
The
programme focussed on the separation of GSK into two separate
companies and is now largely complete. The programme has delivered
its target of £1.1 billion of annual savings, with total costs
still expected at £2.4 billion, with slightly higher cash
charges of £1.7 billion but lower non-cash charges of
£0.7 billion.
Costs
of significant acquisitions relate to integration costs of Sierra
Oncology Inc. (Sierra) and Affinivax Inc. (Affinivax) which were
acquired in Q3 2022, BELLUS Health Inc. (Bellus) acquired in Q2
2023 and Aiolos acquired in Q1 2024.
Cash
charges of £48 million under Legacy programmes primarily arose
from the divestment of the cephalosporins business.
Transaction-related adjustments
Transaction-related
adjustments resulted in a net charge of £1,881 million (2023:
£572 million net charge), the majority of which related to
charges/(credits) for the remeasurement of contingent consideration
liabilities, the liabilities for the Pfizer put option, and Pfizer
and Shionogi preferential dividends in ViiV
Healthcare.
|
|
|
|
|
|
Charge/(credit)
|
2024
£m
|
|
2023
£m
|
|
|
|
|
|
|
Contingent
consideration on former Shionogi-ViiV Healthcare joint
Venture
(including Shionogi preferential dividends)
|
1,533
|
|
934
|
|
ViiV
Healthcare put options and Pfizer preferential
dividends
|
67
|
|
(245)
|
|
Contingent
consideration on former Novartis Vaccines business
|
206
|
|
(187)
|
|
Contingent
consideration on acquisition of Affinivax
|
(22)
|
|
44
|
|
Other
adjustments
|
97
|
|
26
|
|
|
|
|
|
|
Total
transaction-related charges
|
1,881
|
|
572
|
The
£1,533 million charge relating to the contingent consideration
for the former Shionogi-ViiV Healthcare joint venture represented
an increase in the valuation of the contingent consideration due to
Shionogi, driven by £1,107 million from updated future sales
forecasts and exchange rates, and the unwind of the discount for
£426 million. The £67 million charge relating to the ViiV
Healthcare put option and Pfizer preferential dividends represented
an increase in the valuation of the put option primarily as a
result of updated sales forecasts partly offset by higher
preference dividends. The ViiV Healthcare contingent consideration
liability is fair valued under IFRS. An explanation of the
accounting for the non-controlling interests in ViiV Healthcare is
set out on page 18.
The
£206 million charge relating to the contingent consideration
on the former Novartis Vaccines business primarily related to
changes to future sales forecasts.
The
£22 million credit relating to the contingent consideration on
the acquisition of Affinivax primarily related to updated milestone
payment dates partly offset by the unwind of the
discount.
Significant legal charges, Divestments, and other
items
Significant
legal charges in the full year primarily reflected the Q3 2024
charge of £1.8 billion ($2.3 billion) in relation to
Zantac for the State Courts
Settlement, the Qui Tam
Settlement, and the remaining 7% of pending state court product
liability cases, partially offset by reduced future legal
costs.
Legal
charges provide for all significant legal matters and are not
broken out separately by litigation or investigation.
Divestments
and other items primarily included other net income from milestones
and dividends related to investments, as well as amounts
reclassified from the foreign currency translation reserve to the
income statement upon the liquidation of subsidiaries.
The
reconciliations between Total results and Core results for Q4 2024
and Q4 2023 are set out below.
Three months ended 31 December 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
results
£m
|
|
Intangible
amort-
isation
£m
|
|
Intangible
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Significant
legal,
Divest-
ments
and
other
items
£m
|
|
Core
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
8,117
|
|
|
|
|
|
|
|
|
|
|
|
8,117
|
|
Cost of
sales
|
(2,559)
|
|
183
|
|
|
|
22
|
|
|
|
15
|
|
(2,339)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
5,558
|
|
183
|
|
|
|
22
|
|
|
|
15
|
|
5,778
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,663)
|
|
|
|
|
|
35
|
|
1
|
|
(75)
|
|
(2,702)
|
|
Research
and development
|
(2,031)
|
|
15
|
|
196
|
|
(1)
|
|
|
|
|
|
(1,821)
|
|
Royalty
income
|
176
|
|
|
|
|
|
|
|
|
|
|
|
176
|
|
Other
operating income/(expense)
|
(344)
|
|
|
|
|
|
16
|
|
417
|
|
(89)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
696
|
|
198
|
|
196
|
|
72
|
|
418
|
|
(149)
|
|
1,431
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance expense
|
(139)
|
|
|
|
|
|
|
|
|
|
1
|
|
(138)
|
|
Profit/(loss)
on disposal of interests in associates and joint
ventures
|
6
|
|
|
|
|
|
|
|
|
|
(6)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
563
|
|
198
|
|
196
|
|
72
|
|
418
|
|
(154)
|
|
1,293
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(62)
|
|
(36)
|
|
(35)
|
|
(11)
|
|
(11)
|
|
(19)
|
|
(174)
|
|
Tax rate %
|
11.0%
|
|
|
|
|
|
|
|
|
|
|
|
13.5%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
501
|
|
162
|
|
161
|
|
61
|
|
407
|
|
(173)
|
|
1,119
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to non-controlling interests
|
87
|
|
|
|
|
|
|
|
86
|
|
|
|
173
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit/(loss) attributable to shareholders
|
414
|
|
162
|
|
161
|
|
61
|
|
321
|
|
(173)
|
|
946
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
501
|
|
162
|
|
161
|
|
61
|
|
407
|
|
(173)
|
|
1,119
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
10.1p
|
|
4.0p
|
|
3.9p
|
|
1.5p
|
|
7.9p
|
|
(4.2)p
|
|
23.2p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares (millions)
|
4,081
|
|
|
|
|
|
|
|
|
|
|
|
4,081
|
Three months ended 31 December 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
results
£m
|
|
Intangible
amort-
isation
£m
|
|
Intangible
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Significant
legal,
Divest-
ments
and
other
items
£m
|
|
Core
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
8,052
|
|
|
|
|
|
|
|
|
|
|
|
8,052
|
|
Cost of
sales
|
(2,418)
|
|
170
|
|
|
|
67
|
|
13
|
|
5
|
|
(2,163)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
5,634
|
|
170
|
|
|
|
67
|
|
13
|
|
5
|
|
5,889
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,678)
|
|
|
|
|
|
53
|
|
12
|
|
25
|
|
(2,588)
|
|
Research
and development
|
(2,047)
|
|
14
|
|
249
|
|
(2)
|
|
|
|
2
|
|
(1,784)
|
|
Royalty
income
|
235
|
|
|
|
|
|
|
|
|
|
|
|
235
|
|
Other
operating income/(expense)
|
(571)
|
|
|
|
|
|
|
|
430
|
|
141
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
573
|
|
184
|
|
249
|
|
118
|
|
455
|
|
173
|
|
1,752
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance expense
|
(193)
|
|
|
|
|
|
|
|
|
|
2
|
|
(191)
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Profit before taxation
|
379
|
|
184
|
|
249
|
|
118
|
|
455
|
|
175
|
|
1,560
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
19
|
|
(38)
|
|
(59)
|
|
(31)
|
|
(71)
|
|
(55)
|
|
(235)
|
|
Tax rate %
|
(5.0%)
|
|
|
|
|
|
|
|
|
|
|
|
15.1%
|
|
Profit after taxation
|
398
|
|
146
|
|
190
|
|
87
|
|
384
|
|
120
|
|
1,325
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to non-controlling interests
|
48
|
|
|
|
|
|
|
|
104
|
|
|
|
152
|
|
Profit attributable to shareholders
|
350
|
|
146
|
|
190
|
|
87
|
|
280
|
|
120
|
|
1,173
|
|
|
398
|
|
146
|
|
190
|
|
87
|
|
384
|
|
120
|
|
1,325
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
8.6p
|
|
3.6p
|
|
4.7p
|
|
2.1p
|
|
6.9p
|
|
3.0p
|
|
28.9p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares (millions)
|
4,056
|
|
|
|
|
|
|
|
|
|
|
|
4,056
|
Adjusting items Q4
2024
Major restructuring and integration
Total
Major restructuring charges incurred in Q4 2024 were £72
million (Q4 2023: £118 million), analysed as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q4 2024
|
|
Q4
2023
|
||||||||
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Separation
restructuring programme
|
31
|
|
22
|
|
53
|
|
92
|
|
16
|
|
108
|
|
Significant
acquisitions
|
9
|
|
–
|
|
9
|
|
11
|
|
–
|
|
11
|
|
Legacy
programmes
|
1
|
|
9
|
|
10
|
|
(2)
|
|
1
|
|
(1)
|
|
|
41
|
|
31
|
|
72
|
|
101
|
|
17
|
|
118
|
The
Separation restructuring programme incurred cash charges of
£31 million primarily from restructuring of some commercial
and administrative functions as well as Global Supply Chain. The
non-cash charges of £22 million primarily reflected the write
down of assets in manufacturing locations.
Costs
of significant acquisitions relate to integration costs of Sierra
and Affinivax which were acquired in Q3 2022, Bellus acquired in Q2
2023 and Aiolos acquired in Q1 2024.
Transaction-related adjustments
Transaction-related
adjustments resulted in a net charge of £418 million (Q4 2023:
£455 million), the majority of which related to
charges/(credits) for the remeasurement of contingent consideration
liabilities, the liabilities for the Pfizer put option, and Pfizer
and Shionogi preferential dividends in ViiV
Healthcare.
|
|
|
|
|
|
Charge/(credit)
|
Q4 2024
£m
|
|
Q4
2023
£m
|
|
Contingent
consideration on former Shionogi-ViiV Healthcare joint
Venture
(including Shionogi preferential dividends)
|
427
|
|
528
|
|
ViiV
Healthcare put options and Pfizer preferential
dividends
|
13
|
|
(42)
|
|
Contingent
consideration on former Novartis Vaccines business
|
–
|
|
(53)
|
|
Contingent
consideration on acquisition of Affinivax
|
(53)
|
|
(3)
|
|
Other
adjustments
|
31
|
|
25
|
|
|
|
|
|
|
Total
transaction-related charges
|
418
|
|
455
|
The
£427 million charge relating to the contingent consideration
for the former Shionogi-ViiV Healthcare joint venture represented
an increase in the valuation of the contingent consideration due to
Shionogi by £318 million driven by updated exchange rates, and
the unwind of the discount for £109 million. The £13
million charge relating to the ViiV Healthcare put option and
Pfizer preferential dividends represented updated exchange rates
partly offset by a decrease in the valuation of the put option
primarily as a result of updated forecasts. The ViiV Healthcare
contingent consideration liability is fair valued under IFRS. An
explanation of the accounting for the non-controlling interests in
ViiV Healthcare is set out on page 18.
There
was minimal adjustment in the quarter relating to the contingent
consideration on the former Novartis Vaccines business primarily
related to changes to future sales forecasts and the unwind of the
discount being offset by updated exchange rates.
The
£53 million credit relating to the contingent consideration on
the acquisition of Affinivax primarily related to updated milestone
payment dates partly offset by the unwind of the
discount.
Significant legal charges, Divestments, and other
items
Legal
charges provide for all significant legal matters, including
Zantac, and are not broken
out separately by litigation or investigation.
Divestments
and other items included other net income, including milestones and
royalty income, and amounts reclassified from the foreign currency
translation reserve to the income statement upon the liquidation of
subsidiaries.
Financial
information
Income statement
|
|
|
|
|
|
|
|
|
|
|
2024
£m
|
|
2023
£m
|
|
Q4 2024
£m
|
|
Q4
2023
£m
|
|
|
|
|
|
|
|
|
|
|
TURNOVER
|
31,376
|
|
30,328
|
|
8,117
|
|
8,052
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(9,048)
|
|
(8,565)
|
|
(2,559)
|
|
(2,418)
|
|
Gross
profit
|
22,328
|
|
21,763
|
|
5,558
|
|
5,634
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(11,015)
|
|
(9,385)
|
|
(2,663)
|
|
(2,678)
|
|
Research
and development
|
(6,401)
|
|
(6,223)
|
|
(2,031)
|
|
(2,047)
|
|
Royalty
income
|
639
|
|
953
|
|
176
|
|
235
|
|
Other
operating income/(expense)
|
(1,530)
|
|
(363)
|
|
(344)
|
|
(571)
|
|
|
|
|
|
|
|
|
|
|
OPERATING PROFIT
|
4,021
|
|
6,745
|
|
696
|
|
573
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
122
|
|
115
|
|
34
|
|
29
|
|
Finance
expense
|
(669)
|
|
(792)
|
|
(173)
|
|
(222)
|
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
(3)
|
|
(5)
|
|
–
|
|
(1)
|
|
Profit/(loss)
on disposal of interests in associates and joint
ventures
|
6
|
|
1
|
|
6
|
|
–
|
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE TAXATION
|
3,477
|
|
6,064
|
|
563
|
|
379
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(526)
|
|
(756)
|
|
(62)
|
|
19
|
|
Tax rate %
|
15.1%
|
|
12.5%
|
|
11.0%
|
|
(5.0%)
|
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAXATION
|
2,951
|
|
5,308
|
|
501
|
|
398
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
376
|
|
380
|
|
87
|
|
48
|
|
Profit/(loss)
attributable to shareholders
|
2,575
|
|
4,928
|
|
414
|
|
350
|
|
|
2,951
|
|
5,308
|
|
501
|
|
398
|
|
|
|
|
|
|
|
|
|
|
EARNINGS PER SHARE
|
63.2p
|
|
121.6p
|
|
10.1p
|
|
8.6p
|
|
|
|
|
|
|
|
|
|
|
Diluted
earnings per share
|
62.2p
|
|
119.9p
|
|
10.0p
|
|
8.5p
|
|
|
|
|
|
|
|
|
|
Statement of comprehensive income
|
|
|
|
|
|
|
|
|
|
|
2024
£m
|
|
2023
£m
|
|
Q4 2024
£m
|
|
Q4
2023
£m
|
|
|
|
|
|
|
|
|
|
|
Total
profit for the period
|
2,951
|
|
5,308
|
|
501
|
|
398
|
|
|
|
|
|
|
|
|
|
|
Items that may be reclassified subsequently to income
statement:
|
|
|
|
|
|
|
|
|
Exchange
movements on overseas net assets and net
investment hedges
|
(392)
|
|
(22)
|
|
(345)
|
|
65
|
|
Reclassification
of exchange movements on liquidation or
disposal of overseas subsidiaries and associates
|
(87)
|
|
(34)
|
|
(31)
|
|
(14)
|
|
Fair
value movements on cash flow hedges
|
–
|
|
(1)
|
|
1
|
|
(2)
|
|
Cost of
hedging
|
(4)
|
|
–
|
|
1
|
|
–
|
|
Deferred
tax on fair value movements on cash flow hedges
|
1
|
|
1
|
|
2
|
|
2
|
|
Reclassification
of cash flow hedges to income statement
|
4
|
|
4
|
|
–
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
(478)
|
|
(52)
|
|
(372)
|
|
51
|
|
|
|
|
|
|
|
|
|
|
Items that will not be reclassified to income
statement:
|
|
|
|
|
|
|
|
|
Exchange
movements on overseas net assets of
non-controlling interests
|
(4)
|
|
(25)
|
|
13
|
|
(8)
|
|
Fair
value movements on equity investments
|
(100)
|
|
(244)
|
|
8
|
|
115
|
|
Tax on
fair value movements on equity investments
|
17
|
|
14
|
|
11
|
|
(21)
|
|
Fair
value movements on cash flow hedges
|
8
|
|
(40)
|
|
6
|
|
(6)
|
|
Remeasurement
gains/(losses) on defined benefit plans
|
506
|
|
71
|
|
133
|
|
287
|
|
Tax on
remeasurement losses/(gains) on defined benefit
plans
|
(122)
|
|
(41)
|
|
(35)
|
|
(96)
|
|
|
|
|
|
|
|
|
|
|
|
305
|
|
(265)
|
|
136
|
|
271
|
|
|
|
|
|
|
|
|
|
|
Other
comprehensive income/(expense) for the period
|
(173)
|
|
(317)
|
|
(236)
|
|
322
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the period
|
2,778
|
|
4,991
|
|
265
|
|
720
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the period attributable to:
|
|
|
|
|
|
|
|
|
Shareholders
|
2,406
|
|
4,636
|
|
165
|
|
680
|
|
Non-controlling interests
|
372
|
|
355
|
|
100
|
|
40
|
|
|
|
|
|
|
|
|
|
|
|
2,778
|
|
4,991
|
|
265
|
|
720
|
Balance sheet
|
|
|
|
|
|
|
31 December 2024
£m
|
|
31
December 2023
£m
|
|
ASSETS
|
|
|
|
|
Non-current assets
|
|
|
|
|
Property,
plant and equipment
|
9,227
|
|
9,020
|
|
Right
of use assets
|
846
|
|
937
|
|
Goodwill
|
6,982
|
|
6,811
|
|
Other
intangible assets
|
15,515
|
|
14,768
|
|
Investments
in associates and joint ventures
|
96
|
|
55
|
|
Other
investments
|
1,100
|
|
1,137
|
|
Deferred
tax assets
|
6,757
|
|
6,049
|
|
Derivative
instruments
|
1
|
|
–
|
|
Other
non-current assets
|
1,942
|
|
1,584
|
|
|
|
|
|
|
Total non-current assets
|
42,466
|
|
40,361
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
Inventories
|
5,669
|
|
5,498
|
|
Current
tax recoverable
|
489
|
|
373
|
|
Trade
and other receivables
|
6,836
|
|
7,385
|
|
Derivative
financial instruments
|
109
|
|
130
|
|
Current
equity investments
|
–
|
|
2,204
|
|
Liquid
investments
|
21
|
|
42
|
|
Cash
and cash equivalents
|
3,870
|
|
2,936
|
|
Assets
held for sale
|
3
|
|
76
|
|
|
|
|
|
|
Total current assets
|
16,997
|
|
18,644
|
|
|
|
|
|
|
TOTAL ASSETS
|
59,463
|
|
59,005
|
|
|
|
|
|
|
LIABILITIES
|
|
|
|
|
Current liabilities
|
|
|
|
|
Short-term
borrowings
|
(2,349)
|
|
(2,813)
|
|
Contingent
consideration liabilities
|
(1,172)
|
|
(1,053)
|
|
Trade
and other payables
|
(15,335)
|
|
(15,844)
|
|
Derivative
financial instruments
|
(192)
|
|
(114)
|
|
Current
tax payable
|
(703)
|
|
(500)
|
|
Short-term
provisions
|
(1,946)
|
|
(744)
|
|
|
|
|
|
|
Total current liabilities
|
(21,697)
|
|
(21,068)
|
|
|
|
|
|
|
Non-current liabilities
|
|
|
|
|
Long-term
borrowings
|
(14,637)
|
|
(15,205)
|
|
Corporation
tax payable
|
–
|
|
(75)
|
|
Deferred
tax liabilities
|
(382)
|
|
(311)
|
|
Pensions
and other post-employment benefits
|
(1,864)
|
|
(2,340)
|
|
Other
provisions
|
(589)
|
|
(495)
|
|
Contingent
consideration liabilities
|
(6,108)
|
|
(5,609)
|
|
Other
non-current liabilities
|
(1,100)
|
|
(1,107)
|
|
|
|
|
|
|
Total non-current liabilities
|
(24,680)
|
|
(25,142)
|
|
|
|
|
|
|
TOTAL LIABILITIES
|
(46,377)
|
|
(46,210)
|
|
|
|
|
|
|
NET ASSETS
|
13,086
|
|
12,795
|
|
|
|
|
|
|
EQUITY
|
|
|
|
|
Share
capital
|
1,348
|
|
1,348
|
|
Share
premium account
|
3,473
|
|
3,451
|
|
Retained
earnings
|
7,796
|
|
7,239
|
|
Other
reserves
|
1,054
|
|
1,309
|
|
|
|
|
|
|
Shareholders’ equity
|
13,671
|
|
13,347
|
|
|
|
|
|
|
Non-controlling
interests
|
(585)
|
|
(552)
|
|
|
|
|
|
|
TOTAL EQUITY
|
13,086
|
|
12,795
|
Statement of changes in equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share
capital
£m
|
|
Share
premium
£m
|
|
Retained
earnings
£m
|
|
Other
reserves
£m
|
|
Share-
holder’s
equity
£m
|
|
Non-
controlling
interests
£m
|
|
Total
equity
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2024
|
1,348
|
|
3,451
|
|
7,239
|
|
1,309
|
|
13,347
|
|
(552)
|
|
12,795
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
for the year
|
|
|
|
|
2,575
|
|
|
|
2,575
|
|
376
|
|
2,951
|
|
Other comprehensive
income/(expense) for the year
|
|
|
|
|
(83)
|
|
(86)
|
|
(169)
|
|
(4)
|
|
(173)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive
income/(expense)
for the year
|
|
|
|
|
2,492
|
|
(86)
|
|
2,406
|
|
372
|
|
2,778
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributions
to non-controlling
interests
|
|
|
|
|
|
|
|
|
|
|
(416)
|
|
(416)
|
|
Dividends
to shareholders
|
|
|
|
|
(2,444)
|
|
|
|
(2,444)
|
|
|
|
(2,444)
|
|
Deconsolidation
of former subsidiary
|
|
|
|
|
|
|
|
|
–
|
|
(2)
|
|
(2)
|
|
Realised
after tax losses on disposal or liquidation of
equity investments
|
|
|
|
|
14
|
|
(14)
|
|
|
|
|
|
–
|
|
Share
of associates and joint ventures realised
profit/(loss) on disposal of equity investments
|
|
|
|
|
52
|
|
(52)
|
|
|
|
|
|
–
|
|
Shares
issued
|
–
|
|
20
|
|
|
|
|
|
20
|
|
|
|
20
|
|
Write-down
on shares held by ESOP Trusts
|
|
|
|
|
(362)
|
|
362
|
|
|
|
|
|
–
|
|
Shares
acquired by ESOP Trusts
|
|
|
2
|
|
457
|
|
(459)
|
|
|
|
|
|
–
|
|
Share-based
incentive plans
|
|
|
|
|
344
|
|
|
|
344
|
|
|
|
344
|
|
Contributions
from non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
9
|
|
9
|
|
Changes
to non-controlling interests
|
|
|
|
|
|
|
|
|
–
|
|
4
|
|
4
|
|
Hedging
gain/loss after taxation transferred to non-
financial assets
|
|
|
|
|
|
|
(6)
|
|
(6)
|
|
|
|
(6)
|
|
Tax on
share-based incentive plans
|
|
|
|
|
4
|
|
|
|
4
|
|
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 31 December 2024
|
1,348
|
|
3,473
|
|
7,796
|
|
1,054
|
|
13,671
|
|
(585)
|
|
13,086
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share
capital
£m
|
|
Share
premium
£m
|
|
Retained
earnings
£m
|
|
Other
reserves
£m
|
|
Share-
holder’s
equity
£m
|
|
Non-
controlling
interests
£m
|
|
Total
equity
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2023
|
1,347
|
|
3,440
|
|
4,363
|
|
1,448
|
|
10,598
|
|
(502)
|
|
10,096
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
for the year
|
|
|
|
|
4,928
|
|
–
|
|
4,928
|
|
380
|
|
5,308
|
|
Other comprehensive
income/(expense) for the year
|
|
|
|
|
(45)
|
|
(247)
|
|
(292)
|
|
(25)
|
|
(317)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive
income/(expense)
for the year
|
|
|
|
|
4,883
|
|
(247)
|
|
4,636
|
|
355
|
|
4,991
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributions
to non-controlling
interests
|
|
|
|
|
|
|
|
|
|
|
(412)
|
|
(412)
|
|
Contributions
from non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
7
|
|
7
|
|
Dividends
to shareholders
|
|
|
|
|
(2,247)
|
|
|
|
(2,247)
|
|
|
|
(2,247)
|
|
Realised
after tax losses on disposal or liquidation of
equity investments
|
|
|
|
|
(26)
|
|
26
|
|
|
|
|
|
–
|
|
Share
of associates and joint ventures realised
profit/(loss) on disposal of equity investments
|
|
|
|
|
(7)
|
|
7
|
|
|
|
|
|
–
|
|
Share
issued
|
1
|
|
9
|
|
|
|
|
|
10
|
|
|
|
10
|
|
Write-down
of shares held by ESOP Trusts
|
|
|
|
|
(324)
|
|
324
|
|
|
|
|
|
–
|
|
Shares
acquired by ESOP Trusts
|
|
|
2
|
|
283
|
|
(285)
|
|
|
|
|
|
–
|
|
Share-based
incentive plans
|
|
|
|
|
307
|
|
|
|
307
|
|
|
|
307
|
|
Hedging
gain/(loss) after taxation transferred to non-
financial assets
|
|
|
|
|
|
|
36
|
|
36
|
|
|
|
36
|
|
Tax on
share-based incentive plans
|
|
|
|
|
7
|
|
|
|
7
|
|
|
|
7
|
|
At 31
December 2023
|
1,348
|
|
3,451
|
|
7,239
|
|
1,309
|
|
13,347
|
|
(552)
|
|
12,795
|
Cash flow statement year ended 31 December 2024
|
|
|
|
|
|
|
2024
£m
|
|
2023
£m
|
|
Profit after tax
|
2,951
|
|
5,308
|
|
Tax on
profits
|
526
|
|
756
|
|
Share
of after tax loss/(profit) of associates and joint
ventures
|
3
|
|
5
|
|
(Profit)/loss
on disposal of interest in associates and joint
ventures
|
(6)
|
|
(1)
|
|
Net
finance expense
|
547
|
|
677
|
|
Depreciation,
amortisation and other adjusting items
|
2,985
|
|
2,849
|
|
(Increase)/decrease
in working capital
|
(175)
|
|
(1,233)
|
|
Contingent
consideration paid
|
(1,235)
|
|
(1,134)
|
|
Increase/(decrease)
in other net liabilities (excluding contingent consideration
paid)
|
2,265
|
|
869
|
|
Cash generated from operations
|
7,861
|
|
8,096
|
|
Taxation
paid
|
(1,307)
|
|
(1,328)
|
|
Total net cash inflow/(outflow) from operating
activities
|
6,554
|
|
6,768
|
|
|
|
|
|
|
Cash flow from investing activities
|
|
|
|
|
Purchase
of property, plant and equipment
|
(1,399)
|
|
(1,314)
|
|
Proceeds
from sale of property, plant and equipment
|
65
|
|
28
|
|
Purchase
of intangible assets
|
(1,583)
|
|
(1,030)
|
|
Proceeds
from sale of intangible assets
|
131
|
|
12
|
|
Purchase
of equity investments
|
(103)
|
|
(123)
|
|
Proceeds
from sale of equity investments
|
2,356
|
|
1,832
|
|
Share
transactions with non-controlling interests
|
(1)
|
|
–
|
|
Purchase
of businesses, net of cash acquired
|
(805)
|
|
(1,457)
|
|
Investment
in joint ventures and associates
|
(43)
|
|
–
|
|
Contingent
consideration paid
|
(19)
|
|
(11)
|
|
Disposal
of businesses
|
(18)
|
|
49
|
|
Interest
received
|
138
|
|
115
|
|
(Increase)/decrease
in liquid investments
|
21
|
|
72
|
|
Dividends
from joint ventures and associates
|
15
|
|
11
|
|
Dividend
and distributions from investments
|
16
|
|
220
|
|
Proceeds
from disposal of associates and Joint ventures
|
–
|
|
1
|
|
Total net cash inflow/(outflow) from investing
activities
|
(1,229)
|
|
(1,595)
|
|
|
|
|
|
|
Cash flow from financing activities
|
|
|
|
|
Issue
of share capital
|
20
|
|
10
|
|
Repayment
of long-term loans
|
(1,615)
|
|
(2,260)
|
|
Issue
of long-term notes
|
1,075
|
|
223
|
|
Net
increase/(decrease) in short-term loans
|
(811)
|
|
(333)
|
|
Increase
in other short-term loans
|
266
|
|
–
|
|
Repayment
of other short-term loans
|
(81)
|
|
–
|
|
Repayment
of lease liabilities
|
(226)
|
|
(197)
|
|
Interest
paid
|
(632)
|
|
(766)
|
|
Dividends
paid to shareholders
|
(2,444)
|
|
(2,247)
|
|
Distribution
to non-controlling interests
|
(416)
|
|
(412)
|
|
Contributions
from non-controlling interests
|
9
|
|
7
|
|
Other
financing items
|
129
|
|
334
|
|
Total net cash inflow/(outflow) from financing
activities
|
(4,726)
|
|
(5,641)
|
|
Increase/(decrease) in cash and bank overdrafts in the
year
|
599
|
|
(468)
|
|
Cash
and bank overdrafts at beginning of year
|
2,858
|
|
3,425
|
|
Exchange
adjustments
|
(54)
|
|
(99)
|
|
Increase/(decrease)
in cash and bank overdrafts in the year
|
599
|
|
(468)
|
|
Cash and bank overdrafts at end of the year
|
3,403
|
|
2,858
|
|
Cash
and bank overdrafts at end of year comprise:
|
|
|
|
|
Cash and cash equivalents
|
3,870
|
|
2,936
|
|
Overdrafts
|
(467)
|
|
(78)
|
|
|
3,403
|
|
2,858
|
Sales tables
Vaccines turnover – year ended 31 December 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
Shingles
|
3,364
|
(2)
|
1
|
|
1,494
|
(21)
|
(18)
|
|
917
|
1
|
3
|
|
953
|
45
|
52
|
|
Shingrix
|
3,364
|
(2)
|
1
|
|
1,494
|
(21)
|
(18)
|
|
917
|
1
|
3
|
|
953
|
45
|
52
|
|
Meningitis
|
1,437
|
14
|
18
|
|
662
|
9
|
12
|
|
483
|
12
|
14
|
|
292
|
35
|
43
|
|
Bexsero
|
1,010
|
19
|
23
|
|
364
|
17
|
20
|
|
472
|
13
|
16
|
|
174
|
44
|
56
|
|
Menveo
|
387
|
2
|
5
|
|
298
|
–
|
3
|
|
7
|
(42)
|
(42)
|
|
82
|
19
|
23
|
|
Other
|
40
|
29
|
32
|
|
–
|
–
|
–
|
|
4
|
–
|
–
|
|
36
|
33
|
37
|
|
RSV
|
590
|
(52)
|
(51)
|
|
503
|
(58)
|
(57)
|
|
33
|
>100
|
>100
|
|
54
|
35
|
42
|
|
Arexvy
|
590
|
(52)
|
(51)
|
|
503
|
(58)
|
(57)
|
|
33
|
>100
|
>100
|
|
54
|
35
|
42
|
|
Influenza
|
408
|
(19)
|
(16)
|
|
317
|
(15)
|
(12)
|
|
31
|
(21)
|
(18)
|
|
60
|
(36)
|
(33)
|
|
Fluarix, FluLaval
|
408
|
(19)
|
(16)
|
|
317
|
(15)
|
(12)
|
|
31
|
(21)
|
(18)
|
|
60
|
(36)
|
(33)
|
|
Established Vaccines
|
3,339
|
2
|
6
|
|
1,310
|
4
|
7
|
|
722
|
(3)
|
–
|
|
1,307
|
3
|
7
|
|
Infanrix, Pediarix
|
512
|
(8)
|
(5)
|
|
265
|
(9)
|
(6)
|
|
120
|
(1)
|
2
|
|
127
|
(11)
|
(6)
|
|
Boostrix
|
681
|
11
|
14
|
|
429
|
9
|
12
|
|
137
|
12
|
15
|
|
115
|
17
|
24
|
|
Hepatitis
|
692
|
13
|
17
|
|
389
|
16
|
19
|
|
190
|
7
|
10
|
|
113
|
15
|
19
|
|
Rotarix
|
587
|
(4)
|
(1)
|
|
172
|
(10)
|
(8)
|
|
123
|
4
|
7
|
|
292
|
(4)
|
1
|
|
Synflorix
|
226
|
(18)
|
(15)
|
|
–
|
–
|
–
|
|
11
|
(69)
|
(69)
|
|
215
|
(10)
|
(7)
|
|
Priorix, Priorix Tetra,
Varilrix
|
323
|
22
|
26
|
|
39
|
>100
|
>100
|
|
122
|
(5)
|
(2)
|
|
162
|
35
|
40
|
|
Cervarix
|
72
|
(40)
|
(38)
|
|
–
|
–
|
–
|
|
14
|
(58)
|
(58)
|
|
58
|
(33)
|
(31)
|
|
Other
|
246
|
15
|
19
|
|
16
|
(36)
|
(36)
|
|
5
|
(17)
|
(33)
|
|
225
|
24
|
28
|
|
Vaccines
ex COVID-19
solutions
|
9,138
|
(6)
|
(3)
|
|
4,286
|
(19)
|
(17)
|
|
2,186
|
3
|
5
|
|
2,666
|
17
|
23
|
|
Pandemic vaccines
|
–
|
(100)
|
(100)
|
|
–
|
–
|
–
|
|
–
|
(100)
|
(100)
|
|
–
|
(100)
|
(100)
|
|
Pandemic
adjuvant
|
–
|
(100)
|
(100)
|
|
–
|
–
|
–
|
|
–
|
(100)
|
(100)
|
|
–
|
(100)
|
(100)
|
|
Vaccines
|
9,138
|
(7)
|
(4)
|
|
4,286
|
(19)
|
(17)
|
|
2,186
|
(3)
|
(1)
|
|
2,666
|
16
|
21
|
Vaccines turnover – three months ended 31 December
2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
Shingles
|
848
|
(7)
|
(4)
|
|
416
|
(14)
|
(13)
|
|
250
|
12
|
15
|
|
182
|
(9)
|
(5)
|
|
Shingrix
|
848
|
(7)
|
(4)
|
|
416
|
(14)
|
(13)
|
|
250
|
12
|
15
|
|
182
|
(9)
|
(5)
|
|
Meningitis
|
295
|
8
|
12
|
|
82
|
(17)
|
(16)
|
|
144
|
38
|
42
|
|
69
|
(1)
|
9
|
|
Bexsero
|
227
|
33
|
39
|
|
39
|
8
|
8
|
|
141
|
40
|
45
|
|
47
|
38
|
56
|
|
Menveo
|
50
|
(43)
|
(41)
|
|
43
|
(32)
|
(30)
|
|
2
|
(33)
|
(67)
|
|
5
|
(76)
|
(71)
|
|
Other
|
18
|
20
|
20
|
|
–
|
–
|
–
|
|
1
|
>100
|
>100
|
|
17
|
13
|
13
|
|
RSV
|
158
|
(70)
|
(69)
|
|
116
|
(77)
|
(76)
|
|
27
|
>100
|
>100
|
|
15
|
(55)
|
(48)
|
|
Arexvy
|
158
|
(70)
|
(69)
|
|
116
|
(77)
|
(76)
|
|
27
|
>100
|
>100
|
|
15
|
(55)
|
(48)
|
|
Influenza
|
105
|
11
|
14
|
|
73
|
38
|
42
|
|
17
|
(6)
|
–
|
|
15
|
(37)
|
(38)
|
|
Fluarix, FluLaval
|
105
|
11
|
14
|
|
73
|
38
|
42
|
|
17
|
(6)
|
–
|
|
15
|
(37)
|
(38)
|
|
Established Vaccines
|
806
|
5
|
8
|
|
298
|
20
|
22
|
|
180
|
(5)
|
(2)
|
|
328
|
(1)
|
3
|
|
Infanrix, Pediarix
|
122
|
(17)
|
(15)
|
|
59
|
(12)
|
(10)
|
|
33
|
(21)
|
(19)
|
|
30
|
(21)
|
(18)
|
|
Boostrix
|
149
|
5
|
8
|
|
92
|
18
|
21
|
|
33
|
10
|
13
|
|
24
|
(29)
|
(24)
|
|
Hepatitis
|
171
|
36
|
39
|
|
94
|
57
|
62
|
|
47
|
4
|
9
|
|
30
|
43
|
38
|
|
Rotarix
|
156
|
5
|
9
|
|
35
|
6
|
6
|
|
35
|
21
|
24
|
|
86
|
–
|
6
|
|
Synflorix
|
69
|
44
|
48
|
|
–
|
–
|
–
|
|
4
|
(56)
|
(56)
|
|
65
|
67
|
72
|
|
Priorix, Priorix Tetra,
Varilrix
|
83
|
9
|
14
|
|
13
|
>100
|
>100
|
|
29
|
(6)
|
–
|
|
41
|
2
|
5
|
|
Cervarix
|
6
|
(40)
|
(40)
|
|
–
|
–
|
–
|
|
3
|
–
|
–
|
|
3
|
(57)
|
(57)
|
|
Other
|
50
|
(32)
|
(28)
|
|
5
|
(17)
|
(33)
|
|
(4)
|
>(100)
|
>(100)
|
|
49
|
(27)
|
(21)
|
|
Vaccines
ex COVID-19
solutions
|
2,212
|
(14)
|
(11)
|
|
985
|
(29)
|
(27)
|
|
618
|
15
|
19
|
|
609
|
(7)
|
(3)
|
|
Pandemic vaccines
|
–
|
>(100)
|
>(100)
|
|
–
|
–
|
–
|
|
–
|
(100)
|
(100)
|
|
–
|
–
|
–
|
|
Pandemic
adjuvant
|
–
|
>(100)
|
>(100)
|
|
–
|
–
|
–
|
|
–
|
(100)
|
(100)
|
|
–
|
–
|
–
|
|
Vaccines
|
2,212
|
(14)
|
(12)
|
|
985
|
(29)
|
(27)
|
|
618
|
13
|
17
|
|
609
|
(7)
|
(3)
|
Specialty Medicines turnover – year ended 31 December
2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
HIV
|
7,089
|
10
|
13
|
|
4,792
|
12
|
15
|
|
1,496
|
5
|
8
|
|
801
|
9
|
14
|
|
Dolutegravir
products
|
5,599
|
4
|
7
|
|
3,536
|
3
|
6
|
|
1,316
|
2
|
4
|
|
747
|
7
|
12
|
|
Tivicay
|
1,350
|
(3)
|
1
|
|
781
|
(2)
|
–
|
|
252
|
(6)
|
(4)
|
|
317
|
–
|
5
|
|
Triumeq
|
1,325
|
(14)
|
(11)
|
|
942
|
(12)
|
(10)
|
|
222
|
(21)
|
(19)
|
|
161
|
(14)
|
(9)
|
|
Juluca
|
685
|
4
|
7
|
|
546
|
7
|
10
|
|
127
|
(7)
|
(4)
|
|
12
|
(14)
|
(7)
|
|
Dovato
|
2,239
|
23
|
27
|
|
1,267
|
23
|
26
|
|
715
|
18
|
20
|
|
257
|
43
|
50
|
|
Rukobia
|
161
|
38
|
41
|
|
149
|
35
|
39
|
|
8
|
14
|
14
|
|
4
|
>100
|
>100
|
|
Cabenuva
|
1,013
|
43
|
47
|
|
831
|
42
|
46
|
|
156
|
51
|
54
|
|
26
|
44
|
56
|
|
Apretude
|
279
|
87
|
93
|
|
270
|
81
|
87
|
|
–
|
–
|
–
|
|
9
|
–
|
–
|
|
Other
|
37
|
(40)
|
(37)
|
|
6
|
(68)
|
(68)
|
|
16
|
(30)
|
(26)
|
|
15
|
(25)
|
(20)
|
|
Respiratory/Immunology
and Other
|
3,299
|
9
|
13
|
|
2,193
|
4
|
7
|
|
548
|
17
|
20
|
|
558
|
22
|
32
|
|
Nucala
|
1,784
|
8
|
12
|
|
970
|
(1)
|
2
|
|
450
|
17
|
20
|
|
364
|
24
|
34
|
|
Benlysta
|
1,490
|
10
|
14
|
|
1,222
|
9
|
12
|
|
115
|
16
|
19
|
|
153
|
19
|
27
|
|
Other
|
25
|
19
|
33
|
|
1
|
–
|
–
|
|
(17)
|
(21)
|
(21)
|
|
41
|
21
|
29
|
|
Oncology
|
1,410
|
93
|
98
|
|
1,000
|
>100
|
>100
|
|
337
|
17
|
19
|
|
73
|
59
|
72
|
|
Zejula
|
593
|
13
|
17
|
|
305
|
19
|
22
|
|
231
|
4
|
6
|
|
57
|
30
|
36
|
|
Blenrep
|
2
|
(94)
|
(94)
|
|
(3)
|
(50)
|
>(100)
|
|
5
|
(87)
|
(87)
|
|
–
|
–
|
–
|
|
Jemperli
|
467
|
>100
|
>100
|
|
382
|
>100
|
>100
|
|
74
|
>100
|
>100
|
|
11
|
>100
|
>100
|
|
Ojjaara/Omjjara
|
353
|
>100
|
>100
|
|
316
|
>100
|
>100
|
|
32
|
–
|
–
|
|
5
|
–
|
–
|
|
Other
|
(5)
|
>(100)
|
(100)
|
|
–
|
–
|
–
|
|
(5)
|
>(100)
|
>(100)
|
|
–
|
–
|
>100
|
|
Specialty Medicines
ex COVID-19 solutions
|
11,798
|
16
|
19
|
|
7,985
|
18
|
21
|
|
2,381
|
9
|
12
|
|
1,432
|
15
|
23
|
|
Pandemic
|
12
|
(73)
|
(73)
|
|
10
|
–
|
10
|
|
1
|
(67)
|
(67)
|
|
1
|
(97)
|
>(100)
|
|
Xevudy
|
12
|
(73)
|
(73)
|
|
10
|
–
|
10
|
|
1
|
(67)
|
(67)
|
|
1
|
(97)
|
>(100)
|
|
Specialty Medicines
|
11,810
|
15
|
19
|
|
7,995
|
18
|
21
|
|
2,382
|
9
|
12
|
|
1,433
|
13
|
20
|
Specialty Medicines turnover – three months ended 31 December
2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
HIV
|
1,969
|
11
|
14
|
|
1,398
|
14
|
17
|
|
387
|
3
|
7
|
|
184
|
4
|
11
|
|
Dolutegravir
products
|
1,516
|
5
|
8
|
|
1,016
|
7
|
10
|
|
335
|
1
|
5
|
|
165
|
(1)
|
7
|
|
Tivicay
|
343
|
(2)
|
1
|
|
215
|
1
|
3
|
|
62
|
(9)
|
(6)
|
|
66
|
(3)
|
3
|
|
Triumeq
|
346
|
(14)
|
(11)
|
|
260
|
(11)
|
(9)
|
|
50
|
(24)
|
(20)
|
|
36
|
(20)
|
(13)
|
|
Juluca
|
189
|
7
|
10
|
|
155
|
11
|
12
|
|
32
|
(3)
|
3
|
|
2
|
(50)
|
(25)
|
|
Dovato
|
638
|
24
|
27
|
|
386
|
28
|
31
|
|
191
|
15
|
19
|
|
61
|
24
|
33
|
|
Rukobia
|
51
|
46
|
46
|
|
45
|
32
|
35
|
|
2
|
–
|
–
|
|
4
|
>100
|
>100
|
|
Cabenuva
|
310
|
39
|
43
|
|
256
|
38
|
42
|
|
46
|
44
|
47
|
|
8
|
33
|
50
|
|
Apretude
|
84
|
62
|
65
|
|
81
|
56
|
60
|
|
–
|
–
|
–
|
|
3
|
–
|
–
|
|
Other
|
8
|
(56)
|
(50)
|
|
–
|
>(100)
|
(80)
|
|
4
|
(43)
|
(43)
|
|
4
|
(33)
|
(33)
|
|
Respiratory/Immunology
and Other
|
910
|
5
|
9
|
|
623
|
–
|
2
|
|
139
|
11
|
15
|
|
148
|
31
|
42
|
|
Nucala
|
484
|
3
|
7
|
|
268
|
(8)
|
(7)
|
|
115
|
13
|
18
|
|
101
|
31
|
42
|
|
Benlysta
|
423
|
9
|
12
|
|
356
|
7
|
9
|
|
30
|
15
|
19
|
|
37
|
23
|
33
|
|
Other
|
3
|
–
|
33
|
|
(1)
|
>(100)
|
(26)
|
|
(6)
|
(100)
|
>(100)
|
|
10
|
67
|
83
|
|
Oncology
|
408
|
67
|
72
|
|
299
|
83
|
87
|
|
88
|
26
|
30
|
|
21
|
91
|
>100
|
|
Zejula
|
143
|
(6)
|
(3)
|
|
73
|
(14)
|
(12)
|
|
57
|
2
|
5
|
|
13
|
18
|
27
|
|
Blenrep
|
1
|
(83)
|
(83)
|
|
–
|
–
|
–
|
|
1
|
(83)
|
(83)
|
|
–
|
–
|
–
|
|
Jemperli
|
149
|
>100
|
>100
|
|
123
|
>100
|
>100
|
|
22
|
>100
|
>100
|
|
4
|
>100
|
>100
|
|
Ojjaara/Omjjara
|
118
|
>100
|
>100
|
|
103
|
>100
|
>100
|
|
11
|
–
|
–
|
|
4
|
–
|
–
|
|
Other
|
(3)
|
–
|
–
|
|
–
|
–
|
–
|
|
(3)
|
(50)
|
(50)
|
|
–
|
100
|
100
|
|
Specialty Medicines
ex COVID-19 solutions
|
3,287
|
14
|
18
|
|
2,320
|
15
|
18
|
|
614
|
8
|
12
|
|
353
|
17
|
26
|
|
Pandemic
|
11
|
(15)
|
(15)
|
|
10
|
(9)
|
–
|
|
1
|
(50)
|
(50)
|
|
–
|
–
|
–
|
|
Xevudy
|
11
|
(15)
|
(15)
|
|
10
|
(9)
|
–
|
|
1
|
(50)
|
(50)
|
|
–
|
–
|
–
|
|
Specialty Medicines
|
3,298
|
14
|
17
|
|
2,330
|
15
|
18
|
|
615
|
8
|
12
|
|
353
|
17
|
26
|
General Medicines turnover – year ended 31 December
2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
Respiratory
|
7,213
|
6
|
10
|
|
3,869
|
12
|
16
|
|
1,423
|
1
|
4
|
|
1,921
|
(3)
|
4
|
|
Anoro Ellipta
|
572
|
3
|
6
|
|
258
|
(4)
|
(1)
|
|
221
|
15
|
17
|
|
93
|
(2)
|
5
|
|
Flixotide/Flovent
|
527
|
17
|
21
|
|
359
|
27
|
30
|
|
71
|
1
|
3
|
|
97
|
(1)
|
5
|
|
Relvar/Breo Ellipta
|
1,067
|
(3)
|
1
|
|
393
|
(10)
|
(7)
|
|
372
|
2
|
4
|
|
302
|
–
|
8
|
|
Seretide/Advair
|
1,057
|
(7)
|
(3)
|
|
364
|
7
|
10
|
|
219
|
(14)
|
(13)
|
|
474
|
(13)
|
(7)
|
|
Trelegy Ellipta
|
2,702
|
23
|
27
|
|
1,986
|
24
|
27
|
|
312
|
13
|
16
|
|
404
|
26
|
35
|
|
Ventolin
|
702
|
(6)
|
(3)
|
|
362
|
(10)
|
(7)
|
|
107
|
7
|
10
|
|
233
|
(6)
|
(1)
|
|
Other
Respiratory
|
586
|
(6)
|
(1)
|
|
147
|
37
|
41
|
|
121
|
(15)
|
(13)
|
|
318
|
(15)
|
(9)
|
|
Other General Medicines
|
3,215
|
(5)
|
–
|
|
234
|
(16)
|
(14)
|
|
675
|
(7)
|
(5)
|
|
2,306
|
(4)
|
3
|
|
Augmentin
|
635
|
1
|
7
|
|
–
|
–
|
–
|
|
185
|
(1)
|
2
|
|
450
|
2
|
10
|
|
Lamictal
|
405
|
(7)
|
(3)
|
|
163
|
(16)
|
(13)
|
|
106
|
(5)
|
(3)
|
|
136
|
5
|
12
|
|
Other
"Other General
Medicines"
|
2,175
|
(7)
|
(1)
|
|
71
|
(17)
|
(16)
|
|
384
|
(10)
|
(8)
|
|
1,720
|
(5)
|
1
|
|
General Medicines
|
10,428
|
2
|
6
|
|
4,103
|
10
|
13
|
|
2,098
|
(1)
|
1
|
|
4,227
|
(3)
|
3
|
General Medicines turnover – three months ended 31 December
2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
Respiratory
|
1,806
|
3
|
7
|
|
957
|
5
|
7
|
|
368
|
2
|
5
|
|
481
|
2
|
9
|
|
Anoro Ellipta
|
147
|
(5)
|
(2)
|
|
66
|
(15)
|
(14)
|
|
57
|
12
|
14
|
|
24
|
(8)
|
4
|
|
Flixotide/Flovent
|
143
|
43
|
47
|
|
100
|
72
|
76
|
|
20
|
–
|
–
|
|
23
|
5
|
14
|
|
Relvar/Breo Ellipta
|
275
|
(9)
|
(5)
|
|
93
|
(28)
|
(26)
|
|
97
|
2
|
6
|
|
85
|
9
|
15
|
|
Seretide/Advair
|
259
|
(6)
|
(2)
|
|
91
|
17
|
18
|
|
53
|
(18)
|
(17)
|
|
115
|
(14)
|
(7)
|
|
Trelegy Ellipta
|
669
|
14
|
17
|
|
474
|
10
|
12
|
|
82
|
14
|
17
|
|
113
|
30
|
39
|
|
Ventolin
|
170
|
(14)
|
(11)
|
|
86
|
(24)
|
(21)
|
|
31
|
11
|
18
|
|
53
|
(7)
|
(4)
|
|
Other
Respiratory
|
143
|
13
|
20
|
|
47
|
74
|
78
|
|
28
|
(10)
|
(3)
|
|
68
|
–
|
7
|
|
Other General Medicines
|
801
|
(3)
|
3
|
|
55
|
(17)
|
(18)
|
|
154
|
(14)
|
(11)
|
|
592
|
1
|
9
|
|
Augmentin
|
161
|
1
|
10
|
|
–
|
–
|
–
|
|
47
|
(4)
|
–
|
|
114
|
4
|
15
|
|
Lamictal
|
101
|
(6)
|
(3)
|
|
40
|
(18)
|
(16)
|
|
25
|
(11)
|
(7)
|
|
36
|
16
|
23
|
|
Other
"Other General
Medicines"
|
539
|
(4)
|
2
|
|
15
|
(12)
|
(24)
|
|
82
|
(20)
|
(17)
|
|
442
|
—
|
7
|
|
General Medicines
|
2,607
|
1
|
6
|
|
1,012
|
3
|
5
|
|
522
|
(4)
|
–
|
|
1,073
|
2
|
9
|
Commercial Operations turnover
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
Year ended 31 December 2024
|
31,376
|
3
|
7
|
|
16,384
|
4
|
6
|
|
6,666
|
2
|
4
|
|
8,326
|
5
|
11
|
|
Three months ended 31 December 2024
|
8,117
|
1
|
4
|
|
4,327
|
(1)
|
1
|
|
1,755
|
6
|
10
|
|
2,035
|
1
|
8
|
Commercial Operations turnover excluding COVID-19
solutions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
|
|
Growth
|
||||
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
£m
|
£%
|
CER%
|
|
Year ended 31 December 2024
|
31,364
|
4
|
8
|
|
16,374
|
4
|
6
|
|
6,665
|
4
|
6
|
|
8,325
|
5
|
12
|
|
Three months ended 31 December 2024
|
8,106
|
1
|
4
|
|
4,317
|
(1)
|
1
|
|
1,754
|
6
|
10
|
|
2,035
|
1
|
8
|
Segment information
Operating
segments are reported based on the financial information provided
to the Chief Executive Officer and the responsibilities of the GSK
Leadership Team (GLT). GSK reports results under two segments:
Commercial Operations and Total R&D. Members of the GLT are
responsible for each segment.
R&D
investment is essential for the sustainability of the business.
However, for segment reporting the Commercial operating profits
exclude allocations of globally funded R&D.
The
Total R&D segment is the responsibility of the Chief Scientific
Officer and is reported as a separate segment. The operating costs
of this segment includes R&D activities across Specialty
Medicines, including HIV and Vaccines. It includes R&D and some
SG&A costs relating to regulatory and other
functions.
The
Group’s management reporting process allocates intra-Group
profit on a product sale to the market in which that sale is
recorded, and the profit analyses below have been presented on that
basis.
Adjusting
items reconciling segment profit and operating profit comprise
items not specifically allocated to segment profit. These include
impairment and amortisation of intangible assets, major
restructuring costs, which include impairments of tangible assets
and computer software, transaction-related adjustments related to
significant acquisitions, proceeds and costs of disposals of
associates, products and businesses, Significant legal charges and
expenses on the settlement of litigation and government
investigations, other operating income other than royalty income,
and other items including amounts reclassified from the foreign
currency translation reserve to the income statement upon the
liquidation of a subsidiary where the amount exceeds £25
million.
|
|
|
|
|
|
|
|
|
|
Turnover by segment
|
|||||||
|
|
2024
£m
|
|
2023
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations (total turnover)
|
31,376
|
|
30,328
|
|
3
|
|
7
|
|
|
|
|
|
|
|
|
|
|
Operating profit by segment
|
|||||||
|
|
2024
£m
|
|
2023
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
15,335
|
|
14,656
|
|
5
|
|
9
|
|
Research
and Development
|
(5,845)
|
|
(5,607)
|
|
4
|
|
7
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
9,490
|
|
9,049
|
|
5
|
|
11
|
|
Corporate
and other unallocated costs
|
(342)
|
|
(263)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Core
operating profit
|
9,148
|
|
8,786
|
|
4
|
|
11
|
|
Adjusting
items
|
(5,127)
|
|
(2,041)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
4,021
|
|
6,745
|
|
(40)
|
|
(33)
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
122
|
|
115
|
|
|
|
|
|
Finance
costs
|
(669)
|
|
(792)
|
|
|
|
|
|
Share
of after tax profit/(loss) of associates and
joint ventures
|
(3)
|
|
(5)
|
|
|
|
|
|
Profit/(loss)
on disposal of associates and joint ventures
|
6
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation
|
3,477
|
|
6,064
|
|
(43)
|
|
(34)
|
Commercial
Operations Core operating profit of £15,335 million grew in
the full year driven by strong sales and favourable product and
regional mix, as well as price and channel mix benefits and supply
chain efficiencies, and a reversal of the Zejula royalty dispute legal provision
in Q1 2024. This was partly offset by charges to drive future
supply chain efficiencies, continued disciplined investment in
growth assets and lower royalty income.
The
R&D segment operating expense of £5,845 million grew in
the full year driven by continued spend across the portfolio, and
increased investment in Specialty Medicines including camlipixant,
bepirovirsen and Benlysta,
as well as the long acting TSLP asset acquired as part of the
Aiolos acquisition. In Oncology, increased investment in
Jemperli and ADC assets was
offset by investment decreases following the launches of
Ojjaara and progression to
completion of Zejula
studies. In HIV investment on long-acting medicines continued, and
in Vaccines, pneumococcal (MAPS) and mRNA continued to drive
investment.
|
|
|
|
|
|
|
|
|
|
Turnover by segment
|
|||||||
|
|
Q4 2024
£m
|
|
Q4
2023
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations (total turnover)
|
8,117
|
|
8,052
|
|
1
|
|
4
|
|
|
|
|
|
|
|
|
|
|
Operating profit by segment
|
|||||||
|
|
Q4 2024
£m
|
|
Q4
2023
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
3,323
|
|
3,612
|
|
(8)
|
|
(4)
|
|
Research
and Development
|
(1,790)
|
|
(1,731)
|
|
3
|
|
5
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
1,533
|
|
1,881
|
|
(19)
|
|
(12)
|
|
Corporate
and other unallocated costs
|
(102)
|
|
(129)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Core
operating profit
|
1,431
|
|
1,752
|
|
(18)
|
|
(10)
|
|
Adjusting
items
|
(735)
|
|
(1,179)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
696
|
|
573
|
|
21
|
|
54
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
34
|
|
29
|
|
|
|
|
|
Finance
costs
|
(173)
|
|
(222)
|
|
|
|
|
|
Share
of after tax profit/(loss) of associates and
joint ventures
|
–
|
|
(1)
|
|
|
|
|
|
Profit/(loss)
on disposal of associates and joint ventures
|
6
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation
|
563
|
|
379
|
|
49
|
|
97
|
Commercial
Operations Core operating profit of £3,323 million declined in
the quarter. Strong Specialty Medicines sales performance,
favourable product and regional mix as well as price and channel
mix benefits were more than offset by charges to drive future
supply chain efficiencies, continued disciplined investment in
growth assets and lower royalty income.
The
R&D segment operating expense of £1,790 million in the
quarter reflected increased investment in Oncology, driven by ADC
assets, Blenrep and
Jemperli, and Specialty
Medicines, driven by camlipixant and the long acting TSLP asset
acquired as part of the Aiolos acquisition. This was partly offset
by decreased investment in Vaccines reflecting the launch of
Arexvy and timing of
meningitis and mRNA studies.
Legal matters
The
Group is involved in significant legal and administrative
proceedings, principally product liability, intellectual property,
tax, anti-trust, consumer fraud and governmental investigations,
which are more fully described in the ‘Legal
Proceedings’ note in the Annual Report 2023. At 31 December
2024, the Group’s aggregate provision for legal and other
disputes (not including tax matters described on page 9) was
£1,446 million (31 December 2023: £267
million).
The
Group may become involved in significant legal proceedings in
respect of which it is not possible to meaningfully assess whether
the outcome will result in a probable outflow, or to quantify or
reliably estimate the liability, if any, that could result from
ultimate resolution of the proceedings. In these cases, the Group
would provide appropriate disclosures about such cases, but no
provision would be made.
The
ultimate liability for legal claims may vary from the amounts
provided and is dependent upon the outcome of litigation
proceedings, investigations and possible settlement negotiations.
The Group’s position could change over time, and, therefore,
there can be no assurance that any losses that result from the
outcome of any legal proceedings will not exceed by a material
amount the amount of the provisions reported in the Group’s
financial accounts.
Significant
legal developments since the date of the Q3 2024
results:
Product Liability
Zantac
As
previously disclosed, on 9 October 2024 GSK reached agreements to
resolve 93% (approximately 80,000 claimants) of the Zantac state court product liability
cases pending against GSK in the United States. Since that time,
the vast majority of the remaining cases have been resolved or been
dismissed such that less than 1% of the state court cases remain.
GSK is in negotiations with plaintiffs’ counsel on the
remaining cases, including two cases in Nevada state court with
trials scheduled in 2026. The trial in the Mayor & City of
Baltimore action remains scheduled to begin 1 June
2026.
GSK’s
appeal of the Delaware Superior Court’s decision allowing
Plaintiffs to present expert evidence of general causation on all
ten cancer types to a jury remains pending. As previously
disclosed, approximately 14,000 product liability cases were
dismissed following the grant of defendants’ Daubert motions in December 2022 in the
Federal MDL proceeding. These are now on appeal by the plaintiffs
to the United States Court of Appeals for the Eleventh Circuit,
along with appeals in the medical monitoring and consumer class
action cases. GSK remains confident in its position and will
continue to vigorously defend against those appeals.
Intellectual Property
mRNA
On 2
January 2025, Acuitas Therapeutics Inc. filed a declaratory
judgment complaint against GSK, seeking judgment that
COMIRNATY® does not infringe five GSK patents. Acuitas also
seeks a ruling that the patents are invalid. GSK is preparing its
response.
RSV
On 7
October 2024, the London High Court ruled in Pfizer’s favour
and invalidated two of GSK’s patents relating to RSV vaccine
technology. The Court held a hearing on 13 December 2024 at which
GSK sought the Court’s permission to appeal its 7 October
2024 ruling. On 16 January 2025, the Court issued a decision
refusing permission to appeal. GSK is seeking permission to appeal
from the Court of Appeal. Additional decisions are expected in the
Netherlands at any time.
On 14
November 2024, GSK amended its complaint in the United States to
add an additional patent to the case. Trial remains scheduled for 3
August 2026.
Returns to
shareholders
Quarterly dividends
The
Board has declared a fourth interim dividend for Q4 2024 of 16p per
share (Q4 2023: 16p per share).
Dividends
remain an essential component of total shareholder return and GSK
recognises the importance of dividends to shareholders. On 23 June
2021, at the GSK Investor Update, GSK set out that from 2022 a
progressive dividend policy will be implemented guided by a 40 to
60 per cent pay-out ratio through the investment cycle. Consistent
with this, GSK has declared a dividend of 16p for Q4 2024 and 61p
per share for full year 2024. The expected dividend for 2025 is 64p
per share. In setting its dividend policy, GSK considers the
capital allocation priorities of the Group and its investment
strategy for growth alongside the sustainability of the
dividend.
Payment of dividends
The
equivalent interim dividend receivable by ADR holders will be
calculated based on the exchange rate on 8 April 2025. An annual
fee of $0.03 per ADS (or $0.0075 per ADS per quarter) is charged by
the Depositary. The ex-dividend and record dates will be 21
February 2025 with a payment date of 10 April 2025.
|
|
|
|
|
|
|
|
|
Paid/
Payable
|
|
Pence
per
share
|
|
£m
|
|
|
|
|
|
|
|
|
2024
|
|
|
|
|
|
|
First
interim
|
11 July
2024
|
|
15
|
|
612
|
|
Second
interim
|
10
October 2024
|
|
15
|
|
612
|
|
Third
interim
|
9
January 2025
|
|
15
|
|
612
|
|
Fourth
interim
|
10
April 2025
|
|
16
|
|
653
|
|
|
|
|
|
|
|
|
|
|
|
61
|
|
2,489
|
|
2023
|
|
|
|
|
|
|
First
interim
|
13 July
2023
|
|
14
|
|
567
|
|
Second
interim
|
12
October 2023
|
|
14
|
|
568
|
|
Third
interim
|
11
January 2024
|
|
14
|
|
568
|
|
Fourth
interim
|
11
April 2024
|
|
16
|
|
652
|
|
|
|
|
|
|
|
|
|
|
|
58
|
|
2,355
|
Share capital in issue
At 31
December 2024, 4,081 million shares (2023: 4,056 million) were in
free issue (excluding Treasury shares and shares held by the ESOP
Trusts). No Treasury shares have been repurchased since 2014. GSK
expects to implement a £2 billion share buyback programme over
the next 18 months. The company issued 2.2 million shares under
employee share schemes for net proceeds of £20 million (2023:
£10 million).
At 31
December 2024, the ESOP Trusts held 64.3 million shares of GSK
shares, of which 63.7 million were held for the future exercise of
share options and share awards and 0.6 million were held for the
Executive Supplemental Savings plan. The carrying value of
£397 million has been deducted from other reserves.
The market value of these shares was £866
million.
At 31
December 2024, the company held 169 million Treasury shares at a
cost of £2,958 million which has been deducted from
retained earnings.
Weighted average number of shares
The
numbers of shares used in calculating basic and diluted earnings
per share are reconciled below:
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares
|
|||||||
|
|
2024
millions
|
|
2023
millions
|
|
Q4 2024
millions
|
|
Q4
2023
millions
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – basic
|
4,077
|
|
4,052
|
|
4,081
|
|
4,056
|
|
Dilutive
effect of share options and share awards
|
65
|
|
59
|
|
64
|
|
60
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – diluted
|
4,142
|
|
4,111
|
|
4,145
|
|
4,116
|
Additional information
Accounting policies and basis of preparation
This
unaudited Results Announcement contains condensed financial
information for the year-end and three months ended 31 December
2024 and should be read in conjunction with the Annual Report 2023,
which was prepared in accordance with United Kingdom adopted
International Financial Reporting Standards. This Results
Announcement has been prepared applying consistent accounting
policies to those applied by the Group in the Annual Report
2023.
The
Group has not identified any changes to its key sources of
accounting judgements or estimations of uncertainty compared with
those disclosed in the Annual Report 2023.
This
Results Announcement does not constitute statutory accounts of the
Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The full Group accounts for 2023 were published
in the Annual Report 2023, which has been delivered to the
Registrar of Companies and on which the report of the independent
auditor was unqualified and did not contain a statement under
section 498 of the Companies Act 2006.
Exchange rates
GSK
operates in many countries and earns revenues and incurs costs in
many currencies. The results of the Group, as reported in Sterling,
are affected by movements in exchange rates between Sterling and
other currencies. Average exchange rates, as modified by specific
transaction rates for large transactions, prevailing during the
period, are used to translate the results and cash flows of
overseas subsidiaries, associates and joint ventures into Sterling.
Period-end rates are used to translate the net assets of those
entities. The currencies which most influenced these translations
and the relevant exchange rates were:
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
2023
|
|
Q4 2024
|
|
Q4
2023
|
||
|
|
|
|
|
|
|
|
|
||
|
Average
rates:
|
|
|
|
|
|
|
|
||
|
|
|
US$/£
|
1.28
|
|
1.24
|
|
1.27
|
|
1.25
|
|
|
|
Euro/£
|
1.18
|
|
1.15
|
|
1.20
|
|
1.15
|
|
|
|
Yen/£
|
193
|
|
175
|
|
195
|
|
183
|
|
|
|
|
|
|
|
|
|
||
|
Period-end
rates:
|
|
|
|
|
|
|
|
||
|
|
|
US$/£
|
1.25
|
|
1.27
|
|
1.25
|
|
1.27
|
|
|
|
Euro/£
|
1.20
|
|
1.15
|
|
1.20
|
|
1.15
|
|
|
|
Yen/£
|
197
|
|
180
|
|
197
|
|
180
|
Contingent liabilities
There
were contingent liabilities at 31 December 2024 in respect of
arrangements entered into as part of the ordinary course of the
Group’s business. No material losses are expected to arise
from such contingent liabilities. Provision is made for the outcome
of legal and tax disputes where it is both probable that the Group
will suffer an outflow of funds and it is possible to make a
reliable estimate of that outflow. Descriptions of the Significant
legal disputes to which the Group is a party are set out on page
35, and pages 263 to 266 of the 2023 Annual Report.
Net assets
The
book value of net assets increased by £291 million from
£12,795 million at 31 December 2023 to £13,086 million at
31 December 2024. This primarily reflected contribution from Total
comprehensive income for the period partly offset by dividends paid
to shareholders.
At 31
December 2024, the net deficit on the Group’s pension plans
was £103 million compared with £763 million at 31
December 2023. This decrease in the net deficit is primarily due to
an increase in the UK and US discount rates, and pension
contributions.
The
estimated present value of the potential redemption amount of the
Pfizer put option related to ViiV Healthcare, recorded in Other
payables in Current liabilities, was £915 million (31
December 2023: £848 million).
Contingent
consideration amounted to £7,280 million at 31 December 2024
(31 December 2023: £6,662 million), of which £6,061
million (31 December 2023: £5,718 million) represented the
estimated present value of amounts payable to Shionogi relating to
ViiV Healthcare, £575 million (31 December 2023:
£424 million) represented the estimated present value of
contingent consideration payable to Novartis related to the
Vaccines acquisition, £502 million (31 December 2023:
£516 million) represented the estimated present value of
contingent consideration payable in relation to Affinivax, and
£130 million (31 December 2023: £nil) represented the
estimated present value of contingent consideration payable in
relation to the Aiolos acquisition. Of the contingent consideration
payable to Shionogi at 31 December 2024, £1,127 million
(31 December 2023: £1,017 million) is expected to be paid
within one year.
Movements
in contingent consideration are as follows:
|
|
|
|
|
|
2024
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,718
|
|
6,662
|
|
Additions
|
–
|
|
104
|
|
Remeasurement
through income statement and other movements
|
1,533
|
|
1,768
|
|
Cash
payments: operating cash flows
|
(1,190)
|
|
(1,235)
|
|
Cash
payments: investing activities
|
–
|
|
(19)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
6,061
|
|
7,280
|
|
|
|
|
|
|
2023
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,890
|
|
7,068
|
|
Remeasurement
through income statement and other movements
|
934
|
|
739
|
|
Cash
payments: operating cash flows
|
(1,106)
|
|
(1,134)
|
|
Cash
payments: investing activities
|
–
|
|
(11)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
5,718
|
|
6,662
|
|
The
liabilities for the Pfizer put option and the contingent
consideration at 31 December 2024 have been calculated based on the
period-end exchange rates, primarily US$1.25/£1 and
€1.20/£1. Sensitivity analyses for the Pfizer put option
and each of the largest contingent consideration liabilities are
set out below for the following scenarios:
|
|
|
|
|
|
|
|
|
|
|
Increase/(decrease) in financial liability and loss/(gain) in
Income statement
|
ViiV
Healthcare
put
option
£m
|
|
Shionogi-ViiV
Healthcare
contingent
consideration
£m
|
|
Novartis
Vaccines
contingent
consideration
£m
|
|
Affinivax
contingent
consideration
£m
|
|
|
|
|
|
|
|
|
|
|
10%
increase in sales forecasts*
|
92
|
|
573
|
|
83
|
|
n/a
|
|
15%
increase in sales forecasts*
|
139
|
|
857
|
|
125
|
|
n/a
|
|
10%
decrease in sales forecasts*
|
(92)
|
|
(572)
|
|
(83)
|
|
n/a
|
|
15%
decrease in sales forecasts*
|
(138)
|
|
(856)
|
|
(125)
|
|
n/a
|
|
1% (100
basis points) increase in discount rate
|
(22)
|
|
(180)
|
|
(38)
|
|
(14)
|
|
1.5%
(150 basis points) increase in discount rate
|
(32)
|
|
(267)
|
|
(55)
|
|
(20)
|
|
1% (100
basis points) decrease in discount rate
|
23
|
|
194
|
|
43
|
|
14
|
|
1.5%
(150 basis points) decrease in discount rate
|
34
|
|
298
|
|
67
|
|
21
|
|
10 cent
appreciation of US Dollar
|
62
|
|
431
|
|
14
|
|
43
|
|
15 cent
appreciation of US Dollar
|
97
|
|
677
|
|
22
|
|
68
|
|
10 cent
depreciation of US Dollar
|
(53)
|
|
(368)
|
|
(12)
|
|
(37)
|
|
15 cent
depreciation of US Dollar
|
(76)
|
|
(533)
|
|
(17)
|
|
(54)
|
|
10 cent
appreciation of Euro
|
20
|
|
77
|
|
22
|
|
n/a
|
|
15 cent
appreciation of Euro
|
31
|
|
123
|
|
35
|
|
n/a
|
|
10 cent
depreciation of Euro
|
(17)
|
|
(65)
|
|
(19)
|
|
n/a
|
|
15 cent
depreciation of Euro
|
(24)
|
|
(95)
|
|
(27)
|
|
n/a
|
|
10%
increase in probability of milestone success
|
n/a
|
|
n/a
|
|
22
|
|
73
|
|
10%
decrease in probability of milestone success
|
n/a
|
|
n/a
|
|
(11)
|
|
(73)
|
|
|
|
|
*
|
The sales forecast is for ViiV
Healthcare sales only in respect of the ViiV Healthcare put option
and the Shionogi-ViiV Healthcare contingent
consideration.
|
Business acquisitions
On 9
January 2024, GSK announced it had entered into an agreement to
acquire 100% of Aiolos Bio, Inc. (Aiolos), a clinical stage
biopharmaceutical company focused on addressing the unmet treatment
needs of patients with certain respiratory and inflammatory
conditions, for a total consideration of US$1,004 million
(£800 million) as adjusted for working capital acquired
paid upon closing and up to US$400 million
(£319 million) in certain success-based regulatory
milestone payments. The estimated fair value of the contingent
consideration payable was US$120 million
(£96 million). In addition, GSK will also be responsible
for success-based milestone payments as well as tiered royalties
owed to Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui). The
acquisition completed on 14 February 2024.
Goodwill
of £191 million has been recognised. The goodwill represents
specific synergies available to GSK from the business combination.
The goodwill has been allocated to the Group’s R&D
segment.
The
fair values of the net assets acquired, including goodwill, are as
follows:
|
|
|
|
|
|
|
|
|
£m
|
|
Net
assets acquired:
|
|
|
|
|
Intangible
assets
|
|
|
886
|
|
Cash
and cash equivalents
|
|
|
23
|
|
Other
net liabilities
|
|
|
(16)
|
|
Deferred
tax liabilities
|
|
|
(188)
|
|
|
|
|
705
|
|
Goodwill
|
|
|
191
|
|
Total
consideration
|
|
|
896
|
As at
31 December 2024, the present value of the contingent consideration
payable was £130 million.
On 6
June 2024, GSK announced that it had acquired Elsie
Biotechnologies, a San Diego-based private biotechnology company
dedicated to unlocking the full potential of oligonucleotide
therapeutics, for a total cash consideration of up to
US$51 million (approximately £40 million). The
acquisition is accounted for as a business combination but is not
considered a significant acquisition for the Group. This agreement
was not subject to closing conditions and the acquisition has been
completed.
Net debt information
|
Reconciliation of cash flow to movements in net debt
|
|
|
|
|
|
|
|
2024
£m
|
|
2023
£m
|
|
Total
Net debt at beginning of the period
|
(15,040)
|
|
(17,197)
|
|
Increase/(decrease)
in cash and bank overdrafts
|
599
|
|
(468)
|
|
Increase/(decrease)
in liquid investments
|
(21)
|
|
(72)
|
|
Repayment
of long-term loans(1)
|
1,615
|
|
2,260
|
|
Issue
of long-term notes
|
(1,075)
|
|
(223)
|
|
Net
(increase)/decrease in short-term loans
|
811
|
|
333
|
|
Increase
in other short-term loans(2)
|
(266)
|
|
–
|
|
Repayment
of other short-term loans(2)
|
81
|
|
–
|
|
Repayment
of lease liabilities
|
226
|
|
197
|
|
Net
debt of subsidiary undertakings acquired
|
–
|
|
50
|
|
Exchange
adjustments
|
117
|
|
554
|
|
Other
non-cash movements
|
(142)
|
|
(474)
|
|
(Increase)/decrease
in net debt
|
1,945
|
|
2,157
|
|
Total
Net debt at end of the period
|
(13,095)
|
|
(15,040)
|
|
(1)
|
Repayment of long-term loans for
2024 of £1,615 million (2023 : £2,260 million) includes
the current portion of long-term borrowings of £1,615 million
(2023: £2,116 million) which was classified as short term
borrowing on the balance sheet and previously presented as
repayment of short-term loans.
|
|
(2)
|
Other short-term loans include bank
loans presented within short-term borrowings on the balance sheet,
with an initial maturity of greater than three
months.
|
|
Net debt analysis
|
|
|
|
|
|
|
|
31 December 2024
£m
|
|
31
December 2023
£m
|
|
Liquid
investments
|
21
|
|
42
|
|
Cash
and cash equivalents
|
3,870
|
|
2,936
|
|
Short-term
borrowings
|
(2,349)
|
|
(2,813)
|
|
Long-term
borrowings
|
(14,637)
|
|
(15,205)
|
|
Total
Net debt at the end of the period
|
(13,095)
|
|
(15,040)
|
|
Free cash flow reconciliation
|
|
|
|
|
|
|
|
|
|
|
|
2024
£m
|
|
2023
£m
|
|
Q4 2024
£m
|
|
Q4
2023
£m
|
|
|
|
|
|
|
|
|
|
|
Net
cash inflow/(outflow) from operating activities
|
6,554
|
|
6,768
|
|
2,329
|
|
3,196
|
|
Purchase
of property, plant and equipment
|
(1,399)
|
|
(1,314)
|
|
(544)
|
|
(486)
|
|
Proceeds
from sale of property, plant and equipment
|
65
|
|
28
|
|
61
|
|
7
|
|
Purchase
of intangible assets
|
(1,583)
|
|
(1,030)
|
|
(591)
|
|
(297)
|
|
Proceeds
from disposals of intangible assets
|
131
|
|
12
|
|
5
|
|
–
|
|
Net
finance costs
|
(494)
|
|
(651)
|
|
(200)
|
|
(254)
|
|
Dividends
from associates and joint ventures
|
15
|
|
12
|
|
–
|
|
11
|
|
Contingent
consideration paid (reported in investing
activities)
|
(19)
|
|
(11)
|
|
(8)
|
|
(4)
|
|
Distributions
to non-controlling interests
|
(416)
|
|
(412)
|
|
(128)
|
|
(78)
|
|
Contributions
from non-controlling interests
|
9
|
|
7
|
|
–
|
|
–
|
|
|
|
|
|
|
|
|
|
|
Free
cash inflow/(outflow)
|
2,863
|
|
3,409
|
|
924
|
|
2,095
|
|
Reconciliation of Total Operating Profit to Core
EBITDA
|
The
Total net debt/Core EBITDA ratio is disclosed solely for the
purpose of demonstrating a leverage ratio that is used by analysts,
investors and other stakeholders and which assesses the strength of
the balance sheet. It is calculated at the end of the financial
reporting year.
|
|
|
|
|
|
|
2024
£m
|
|
2023
£m
|
|
Total
Operating profit
|
4,021
|
|
6,745
|
|
Adjusting
items
|
5,127
|
|
2,041
|
|
Core
Operating profit
|
9,148
|
|
8,786
|
|
|
|
|
|
|
Including:
|
|
|
|
|
Share of after tax profit/(loss) of associates and joint
venture
|
(3)
|
|
(5)
|
|
Excluding:
|
|
|
|
|
Core depreciation
|
1,096
|
|
1,081
|
|
Core amortisation
|
452
|
|
493
|
|
|
|
|
|
|
Core
EBITDA
|
10,693
|
|
10,355
|
Total Net debt to Core EBITDA ratio
|
|
|
|
|
|
|
2024
£m
|
|
2023
£m
|
|
Total
Net debt
|
13,095
|
|
15,040
|
|
Core
EBITDA
|
10,693
|
|
10,355
|
|
Total
Net debt to Core EBITDA ratio
|
1.2
|
|
1.5
|
Post balance sheet event
On 13
January 2025, GSK announced it had entered into an agreement to
acquire IDRx, Inc. (IDRx) a clinical-stage biopharmaceutical
company dedicated to transforming cancer care with intelligently
designed precision therapies. The acquisition includes lead
molecule, IDRX-42, a highly selective investigational small
molecule tyrosine kinase inhibitor (TKI) being developed as a
first- and second-line therapy for the treatment of
gastrointestinal stromal tumours.
GSK will acquire all of the outstanding equity interests (including
all options and other incentive equity) in IDRx for up to US$1.15
billion of total cash consideration, comprising an upfront payment
of US$1 billion with potential for an additional US$150 million
success-based regulatory approval milestone payment. GSK will also
be responsible for success-based milestone payments as well as
tiered royalties for IDRX-42 owed to Merck KGaA, Darmstadt,
Germany. The transaction is subject to customary conditions,
including applicable regulatory agency clearances under the
Hart-Scott-Rodino Act in the US and is expected to close in the
first quarter of 2025.
Related party transactions
Details
of GSK’s related party transactions are disclosed on page 235
of our 2023 Annual Report.
R&D commentary
|
Pipeline overview
|
|
Medicines
and vaccines in phase III development (including major lifecycle
innovation or under regulatory review)
|
19
|
Respiratory, Immunology and Inflammation (6)
|
|
|
●
|
Nucala (anti-IL5 biologic) chronic obstructive pulmonary
disease
|
||
|
●
|
depemokimab
(ultra long-acting anti-IL5 biologic) severe eosinophilic asthma,
eosinophilic granulomatosis with polyangiitis (EGPA), chronic
rhinosinusitis with nasal polyps (CRSwNP), hyper-eosinophilic
syndrome (HES)
|
||
|
●
|
latozinemab
(AL001, anti-sortilin) frontotemporal dementia
|
||
|
●
|
camlipixant
(P2X3 receptor antagonist) refractory chronic cough
|
||
|
●
|
Ventolin (salbutamol, Beta 2 adrenergic receptor agonist)
asthma
|
||
|
●
|
linerixibat
(IBATi) cholestatic pruritus in primary biliary
cholangitis
|
||
|
Oncology (5)
|
|||
|
●
|
Blenrep (anti-BCMA ADC) multiple myeloma
|
||
|
●
|
Jemperli (anti-PD-1) 1L endometrial cancer, colon cancer,
rectal cancer, head and neck cancer
|
||
|
●
|
Zejula (PARP inhibitor) 1L ovarian and non-small cell lung
cancer, glioblastoma
|
||
|
●
|
belrestotug
(anti-TIGIT) 1L non-small cell lung cancer
|
||
|
●
|
cobolimab
(anti-TIM-3) 2L non-small cell lung cancer
|
||
|
Infectious Diseases (8)
|
|||
|
●
|
Arexvy (RSV vaccine) RSV adults (18-49 years of age at
increased risk (AIR) and 18+ immunocompromised)
|
||
|
●
|
gepotidacin
(bacterial topoisomerase inhibitor) uncomplicated urinary tract
infection and urogenital gonorrhoea
|
||
|
●
|
bepirovirsen
(HBV ASO) hepatitis B virus
|
||
|
●
|
Bexsero (meningococcal B vaccine) infants (US)
|
||
|
●
|
MenABCWY
(gen 1) vaccine candidate
|
||
|
●
|
tebipenem
pivoxil (antibacterial carbapenem) complicated urinary tract
infection
|
||
|
●
|
ibrexafungerp
(antifungal glucan synthase inhibitor) invasive
candidiasis
|
||
|
●
|
GSK4178116
(varicella vaccine) varicella new strain individuals 12 months of
age and older
|
||
|
Total
medicines and vaccines in all phases of clinical
development
|
71
|
|
|
|
Total
projects in clinical development (inclusive of all phases and
indications)
|
90
|
|
|
Therapy area updates
The
following provides updates on key medicines and vaccines by therapy
area that will help drive growth for GSK to meet its future
outlooks.
Respiratory, Immunology and Inflammation
camlipixant (P2X3 receptor antagonist)
Camlipixant
(BLU-5937) is an investigational, highly selective oral P2X3
antagonist currently in development for first-line treatment of
adult patients suffering from refractory chronic cough (RCC). The
CALM phase III development programme to evaluate the efficacy and
safety of camlipixant for use in adults with RCC is
ongoing.
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
CALM-1
(refractory chronic cough)
NCT05599191
|
III
|
A
52-week, randomised, double-blind, placebo-controlled, parallel-arm
efficacy and safety trial with open-label extension of camlipixant
in adult participants with refractory chronic cough, including
unexplained chronic cough
|
Trial
start:
Q4
2022
|
Recruiting
|
|
CALM-2
(refractory chronic cough)
NCT05600777
|
III
|
A
24-week, randomised, double-blind, placebo-controlled, parallel-arm
efficacy and safety trial with open-label extension of camlipixant
in adult participants with refractory chronic cough, including
unexplained chronic cough
|
Trial
start:
Q1
2023
|
Recruiting
|
depemokimab (long acting anti-IL5)
Depemokimab
is in late-stage development in a range of IL-5 mediated conditions
including asthma with type 2 inflammation, chronic rhinosinusitis
with nasal polyps (CRSwNP), hypereosinophilic syndrome (HES) and
eosinophilic granulomatosis with polyangiitis (EGPA). It is the
first ultra-long-acting biologic engineered to have an extended
half-life and high binding affinity and potency for IL-5, enabling
six-month dosing intervals in phase III clinical
trials.
Positive
phase III data from the pivotal SWIFT-1 and SWIFT-2 trials in
asthma with type 2 inflammation and the ANCHOR-1 and ANCHOR-2
trials in patients with CRSwNP are being used to support regulatory
filings in major markets.
Regulatory
submissions seeking approval for the use of depemokimab in patients
with asthma with type 2 inflammation and in patients with CRSwNP,
have been accepted by the health authorities in the EU, China and
Japan. Regulatory acceptance is expected in the US in Q1 2025 with
submissions in other markets expected to progress through the
year.
Key
phase III trials for depemokimab:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
SWIFT-1
(severe eosinophilic asthma)
NCT04719832
|
III
|
A
52-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre trial of the efficacy and safety of
depemokimab adjunctive therapy in adult and adolescent participants
with severe uncontrolled asthma with an eosinophilic
phenotype
|
Trial
start:
Q1
2021
Data
reported:
Q2
2024
|
Completed;
primary endpoint met
|
|
SWIFT-2
(severe eosinophilic asthma)
NCT04718103
|
III
|
A
52-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre trial of the efficacy and safety of
depemokimab adjunctive therapy in adult and adolescent participants
with severe uncontrolled asthma with an eosinophilic
phenotype
|
Trial
start:
Q1
2021
Data
reported:
Q2
2024
|
Completed;
primary endpoint met
|
|
AGILE
(SEA)
NCT05243680
|
III
(exten
sion)
|
A
52-week, open label extension phase of SWIFT-1 and SWIFT-2 to
assess the long-term safety and efficacy of depemokimab adjunctive
therapy in adult and adolescent participants with severe
uncontrolled asthma with an eosinophilic phenotype
|
Trial
start:
Q1
2022
|
Active,
not recruiting
|
|
NIMBLE
(SEA)
NCT04718389
|
III
|
A
52-week, randomised, double-blind, double-dummy, parallel group,
multi-centre, non-inferiority trial assessing exacerbation rate,
additional measures of asthma control and safety in adult and
adolescent severe asthmatic participants with an eosinophilic
phenotype treated with depemokimab compared with mepolizumab or
benralizumab
|
Trial
start:
Q1
2021
|
Active,
not recruiting
|
|
ANCHOR-1
(chronic rhinosinusitis with nasal polyps; CRSwNP)
NCT05274750
|
III
|
Efficacy
and safety of depemokimab in participants with CRSwNP
|
Trial
start:
Q2
2022
Data
reported: Q3 2024
|
Complete;
primary endpoint met
|
|
ANCHOR-2
(CRSwNP)
NCT05281523
|
III
|
Efficacy
and safety of depemokimab in participants with CRSwNP
|
Trial
start:
Q2
2022
Data
reported:
Q3
2024
|
Complete;
primary endpoint met
|
|
OCEAN
(eosinophilic granulomatosis with polyangiitis; EGPA)
NCT05263934
|
III
|
Efficacy
and safety of depemokimab compared with mepolizumab in adults with
relapsing or refractory EGPA
|
Trial
start:
Q3
2022
|
Recruiting
|
|
DESTINY
(hyper-eosinophilic syndrome; HES)
NCT05334368
|
III
|
A
52-week, randomised, placebo-controlled, double-blind, parallel
group, multicentre trial of depemokimab in adults with uncontrolled
HES receiving standard of care (SoC) therapy
|
Trial
start:
Q3
2022
|
Recruiting
|
Nucala (mepolizumab)
Nucala is a first in class anti-IL-5 biologic and the only
treatment approved for use in the US and Europe across four IL-5
medicated conditions: severe asthma with an eosinophilic phenotype,
EGPA, HES and CRSwNP.
In
September 2024, positive results from MATINEE, a phase III trial
investigating Nucala in
patients with chronic obstructive pulmonary disease (COPD) were
announced. MATINEE met its primary endpoint with the addition of
Nucala to inhaled
maintenance therapy showing a statistically significant and
clinically meaningful reduction in the annualised rate of
moderate/severe exacerbations versus placebo, with patients treated
for up to 104 weeks.
Publication
of the full results of MATINEE is expected in Q1 2025. The US FDA
has accepted these data for review as part of the regulatory
process to grant an indication for the use of Nucala in patients with COPD. Further
submissions are planned in 2025.
Key
trials for Nucala:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
MATINEE
(chronic obstructive pulmonary disease; COPD)
NCT04133909
|
III
|
A
multicentre randomised, double-blind, parallel-group,
placebo-controlled trial of mepolizumab 100 mg subcutaneously as
add-on treatment in participants with COPD experiencing frequent
exacerbations and characterised by eosinophil levels
|
Trial
start:
Q4
2019
Data
reported:
Q3
2024
|
Complete;
primary endpoint met
|
Oncology
Blenrep (belantamab
mafodotin)
GSK is
pursuing regulatory approvals worldwide for Blenrep combinations for the treatment
of relapsed or refractory multiple myeloma based on positive
results from the phase III head-to-head DREAMM-7 and DREAMM-8
trials.
In
November 2024, GSK announced positive overall survival (OS) results
from the DREAMM-7 trial evaluating a belantamab mafodotin
combination regimen compared to a standard-of-care daratumumab
combination regimen in relapsed or refractory multiple myeloma.
Full results, presented at the American Society of Hematology (ASH)
Annual Meeting in December, showed a significant overall survival
benefit for the belantamab mafodotin combination, with a 42%
reduction in the risk of death versus standard of
care.
Based
on these data the US FDA has accepted for review a Biologics
License Application for belantamab mafodotin in combinations with
bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus
dexamethasone (PomDex [BPd]) for the treatment of patients with
multiple myeloma who have received at least one prior line of
therapy. The US FDA has assigned a Prescription Drug User Fee Act
action date of 23 July 2025.
A new
drug application also was accepted for priority review in China in
December 2024 for BVd as a treatment for relapsed or refractory
multiple myeloma based on the results of DREAMM-7. The National
Medical Products Administration of China also previously granted
Breakthrough Therapy Designation for the BVd combination, a
designation intended to expedite development of investigational
drugs with potential for substantial improvement over available
therapies.
GSK
continues to explore the potential for belantamab mafodotin to help
address unmet need for patients with multiple myeloma, in early
treatment lines and in combination with novel therapies and
standard of care treatments. In Q4 2024, GSK initiated DREAMM-10, a
phase III trial evaluating belantamab mafodotin plus lenalidomide
and dexamethasone (BRd) versus daratumumab plus lenalidomide and
dexamethasone (DRd) in patients with newly diagnosed transplant
ineligible multiple myeloma.
Key
phase III trials for Blenrep:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
DREAMM-7
(2L+ multiple myeloma; MM)
NCT04246047
|
III
|
A
multi-centre, open-label, randomised trial to evaluate the efficacy
and safety of the combination of belantamab mafodotin, bortezomib,
and dexamethasone (B-Vd) compared with the combination of
daratumumab, bortezomib and dexamethasone (D-Vd) in participants
with relapsed/refractory multiple myeloma
|
Trial
start:
Q2
2020
Primary
data reported:
Q4 2023
|
Active,
not recruiting; primary endpoint met
|
|
DREAMM-8
(2L+ MM)
NCT04484623
|
III
|
A
multi-centre, open-label, randomised trial to evaluate the efficacy
and safety of belantamab mafodotin in combination with pomalidomide
and dexamethasone (B-Pd) versus pomalidomide plus bortezomib and
dexamethasone (P-Vd) in participants with relapsed/refractory
multiple myeloma
|
Trial
start:
Q4
2020
Primary
data reported:
Q1
2024
|
Recruiting,
primary endpoint met
|
|
DREAMM-10
(1L MM)
NCT06679101
|
III
|
A
multi-centre, open-label, randomised trial to evaluate the efficacy
and safety of belantamab mafodotin, lenalidomide and dexamethasone
(B-Rd) versus daratumumab, lenalidomide, and dexamethasone (D-Rd)
in participants with newly diagnosed multiple myeloma who are
ineligible for autologous stem cell transplantation
|
Trial
start:
Q4
2024
|
Recruiting
|
Jemperli (dostarlimab)
Jemperli (dostarlimab) is the foundation of GSK’s
ongoing immuno-oncology-based research and development programme.
In January 2025, the European Commission expanded the approval of
Jemperli in combination
with chemotherapy (carboplatin and paclitaxel) for first-line
treatment of all adult patients with primary advanced or recurrent
endometrial cancer who are candidates for systemic therapy. This
approval broadens the previous indication for Jemperli plus chemotherapy in the EU to
include patients with mismatch repair proficient
(MMRp)/microsatellite stable (MSS) tumours, which represent
approximately 75% of patients diagnosed with endometrial cancer and
who have limited treatment options.
In
December 2024, the US FDA granted Breakthrough Therapy Designation
to dostarlimab for the treatment of patients with locally advanced
mismatch repair deficient (dMMR)/microsatellite instability-high
(MSI-H) rectal cancer. The designation was based on data showing no
evidence of disease in 100% of all 42 patients who completed
treatment with dostarlimab in a phase II trial. This is the second
US regulatory designation to help expedite the development of
dostarlimab in locally advanced dMMR/MSI-H rectal cancer, following
Fast Track designation for the same patient population in January
2023.
Key
trials for Jemperli:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RUBY
(1L stage III or IV endometrial cancer)
NCT03981796
|
III
|
A
randomised, double-blind, multi-centre trial of dostarlimab plus
carboplatin-paclitaxel with and without niraparib maintenance
versus placebo plus carboplatin-paclitaxel in patients with
recurrent or primary advanced endometrial cancer
|
Trial
start:
Q3
2019
Part 1
data reported:
Q4
2022
Part 2
data reported:
Q4
2023
|
Active,
not recruiting; primary endpoints met
|
|
PERLA
(1L metastatic non-small cell lung cancer)
NCT04581824
|
II
|
A
randomised, double-blind trial to evaluate the efficacy of
dostarlimab plus chemotherapy versus pembrolizumab plus
chemotherapy in metastatic non-squamous non-small cell lung
cancer
|
Trial
start:
Q4
2020
Primary
data reported:
Q4
2022
|
Complete;
primary endpoint met
|
|
GARNET
(advanced solid tumours)
NCT02715284
|
I/II
|
A
multi-centre, open-label, first-in-human trial evaluating
dostarlimab in participants with advanced solid tumours who have
limited available treatment options
|
Trial
start:
Q1
2016
Primary
data reported:
Q1
2019
|
Recruiting
|
|
AZUR-1
(locally advanced rectal cancer)
NCT05723562
|
II
|
A
single-arm, open-label trial with dostarlimab monotherapy in
participants with untreated stage II/III dMMR/MSI-H locally
advanced rectal cancer
|
Trial
start:
Q1
2023
|
Active,
not recruiting
|
|
AZUR-2
(untreated perioperative T4N0 or stage III colon
cancer)
NCT05855200
|
III
|
An
open-label, randomised trial of perioperative dostarlimab
monotherapy versus standard of care in participants with untreated
T4N0 or stage III dMMR/MSI-H resectable colon cancer
|
Trial
start:
Q3
2023
|
Recruiting
|
|
COSTAR
Lung (advanced non-small cell lung cancer that has progressed on
prior PD-(L)1 therapy and chemotherapy)
NCT04655976
|
II/III
|
A
multi-centre, randomised, parallel group treatment, open label
trial comparing cobolimab + dostarlimab + docetaxel to dostarlimab
+ docetaxel to docetaxel alone in participants with advanced
non-small cell lung cancer who have progressed on prior
anti-PD-(L)1 therapy and chemotherapy
|
Trial
start:
Q4
2020
|
Active,
not recruiting
|
|
JADE
(locally advanced unresected head and neck cancer)
NCT06256588
|
III
|
A
randomised, double-blind, study to evaluate dostarlimab versus
placebo as sequential therapy after chemoradiation in participants
with locally advanced unresected head and neck squamous cell
carcinoma
|
Trial
start:
Q1
2024
|
Recruiting
|
Zejula (niraparib)
GSK
continues to assess the potential of Zejula across multiple tumour types and
in combination with other agents. The ongoing development programme
includes several phase III combination studies including the RUBY
Part 2 trial of niraparib and dostarlimab in recurrent or primary
advanced endometrial cancer; the FIRST trial of niraparib and
dostarlimab in stage III or IV nonmucinous epithelial ovarian
cancer; and the ZEAL trial of niraparib plus pembrolizumab in
advanced/metastatic non-small cell lung cancer.
In
December 2024, GSK announced that the FIRST-ENGOT-OV44 phase III
trial met its primary endpoint of progression-free survival (PFS).
The topline results showed that the addition of dostarlimab to both
platinum-based chemotherapy and niraparib maintenance, with or
without bevacizumab, had a statistically significant effect on PFS
versus the active comparator arm. The key secondary endpoint of
overall survival did not meet statistical significance. Further
analyses are ongoing, and data will be shared with health
authorities and presented at an upcoming scientific
meeting.
Niraparib
also is being evaluated in patients with newly diagnosed, MGMT
unmethylated glioblastoma in the phase III GLIOFOCUS trial
(NCT06388733) sponsored by the Ivy Brain Tumor Center and supported
by GSK.
Key
ongoing phase III trials for Zejula (see also RUBY Part 2 in
Jemperli
section):
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
ZEAL-1L
(1L advanced non-small cell lung cancer maintenance)
NCT04475939
|
III
|
A
randomised, double-blind, placebo-controlled, multi-centre trial
comparing niraparib plus pembrolizumab versus placebo plus
pembrolizumab as maintenance therapy in participants whose disease
has remained stable or responded to first-line platinum-based
chemotherapy with pembrolizumab for Stage IIIB/IIIC or IV non-small
cell lung cancer
|
Trial
start:
Q4
2020
|
Active,
not recruiting
|
|
FIRST
(1L ovarian cancer maintenance)
NCT03602859
|
III
|
A
randomised, double-blind, comparison of platinum-based therapy with
dostarlimab (TSR-042) and niraparib versus standard of care
platinum-based therapy as first-line treatment of stage III or IV
non-mucinous epithelial ovarian cancer
|
Trial
start:
Q4
2018
Data
reported:
Q4
2024
|
Primary
endpoint met
|
GSK5764227 (GSK’227) B7-H3-targeted antibody-drug
conjugate
GSK is
accelerating its portfolio of antibody-drug conjugates (ADCs) in a
breadth of solid tumours that complement our existing and emerging
capabilities and strengths. GSK’227 is a B7-H3-targeting ADC
that has broad potential due to high expression levels of the B7H3
antigen across multiple tumour types. It is currently being
evaluated alone and in combination with other therapies in phase I
trials of locally advanced or metastatic solid tumours, including
small-cell lung cancer (ES-SCLC) and osteosarcoma (bone cancer),
among others.
In
December 2024, GSK’227 received two regulatory designations
that support its accelerated development in certain tumour types,
further underscoring its transformative potential. The EMA granted
Priority Medicines (PRIME) Designation for the treatment of
patients with relapsed extensive-stage SCLC. PRIME Designation
supports the development of medicines with potential to offer a
major therapeutic advantage for patients. In addition, the FDA
granted Breakthrough Therapy Designation (BTD) for the treatment of
adult patients with relapsed or refractory osteosarcoma who have
progressed on at least two prior lines of therapy. BTD aims to
expedite the development and review of drugs with the potential to
show improvement over currently available therapy for serious
conditions. The FDA previously granted BTD for GSK’227 in
relapsed or refractory ES-SCLC in August 2024.
HIV
GSK
continues to lead in long-acting injectable innovation,
transforming the HIV marketplace.
In
November 2024, ViiV Healthcare presented 42 abstracts at the HIV
Glasgow conference, highlighting the growing body of evidence
supporting the use of long-acting therapies in diverse patient
populations. These studies included new analyses showing the use of
long-acting injectable Vocabria + Rekambys (cabotegravir + rilpivirine
LA) in clinical trial and real-world populations, and the economic
and public health impact of Apretude (cabotegravir LA for
PrEP).
Important
data from the DOLCE study were also shared, demonstrating that
Dovato
(dolutegravir/lamivudine) is highly effective in
treatment-naïve people with advanced HIV. Taking fewer
medicines is important to many people living with HIV and these
data reinforce confidence in Dovato’s safety and efficacy
compared to three-drug regimens.
In
January 2025, the European Commission approved Vocabria + Rekambys for use in adolescents,
marking an important step in bringing this medicine to younger
people living with HIV.
A
registrational study for four-monthly injectable PrEP also began in
December 2024 and a registrational study for a four-monthly
long-acting injectable treatment is on track to start in 2025. In
2026, the assets that will deliver six-monthly dosing are expected
to be confirmed, enabling regimen selection.
Infectious Diseases
Arexvy (respiratory
syncytial virus vaccine, adjuvanted)
In
November 2024, Japan’s Ministry of Health, Labour and Welfare
(MHLW) approved the extended use of Arexvy for the prevention of
respiratory syncytial virus (RSV) disease to include adults aged
50-59 at increased risk, making it the only RSV vaccine approved
for this population in Japan. The vaccine has been approved for use
in adults aged 50-59 at increased risk in 40 out of 58 of the
markets where it is registered with further regulatory reviews
ongoing.
Key
phase III trials for Arexvy:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RSV
OA=ADJ-004
(Adults
≥ 60 years old)
NCT04732871
|
III
|
A
randomised, open-label, multi-country trial to evaluate the
immunogenicity, safety, reactogenicity and persistence of a single
dose of the RSVPreF3 OA investigational vaccine and different
revaccination schedules in adults aged 60 years and
above
|
Trial
start:
Q1
2021
Primary
data reported:
Q2
2022
|
Active,
not recruiting; primary endpoint met
|
|
RSV
OA=ADJ-006
(ARESVI-006;
Adults ≥ 60 years old)
NCT04886596
|
III
|
A
randomised, placebo-controlled, observer-blind, multi-country trial
to demonstrate the efficacy of a single dose of GSK’s
RSVPreF3 OA investigational vaccine in adults aged 60 years and
above
|
Trial
start:
Q2
2021
Primary
data reported:
Q2
2022;
two
season data reported:
Q2
2023;
three
season data reported: Q3 2024
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-007
(Adults
≥ 60 years old)
NCT04841577
|
III
|
An
open-label, randomised, controlled, multi-country trial to evaluate
the immune response, safety and reactogenicity of RSVPreF3 OA
investigational vaccine when co-administered with FLU-QIV vaccine
in adults aged 60 years and above
|
Trial
start:
Q2
2021
Primary
data reported:
Q4
2022
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-008
(Adults
≥ 65 years old)
NCT05559476
|
III
|
A phase
III, open-label, randomised, controlled, multi country trial to
evaluate the immune response, safety and reactogenicity of RSVPreF3
OA investigational vaccine when co-administered with FLU HD vaccine
in adults aged 65 years and above
|
Trial
start:
Q4
2022
Primary
data reported:
Q2
2023
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-009
(Adults
≥ 60 years old)
NCT05059301
|
III
|
A
randomised, double-blind, multi-country trial to evaluate
consistency, safety, and reactogenicity of 3 lots of RSVPreF3 OA
investigational vaccine administrated as a single dose in adults
aged 60 years and above
|
Trial
start:
Q4
2021
Trial
end:
Q2
2022
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-017
(Adults
≥ 65 years old)
NCT05568797
|
III
|
A phase
III, open-label, randomised, controlled, multi-country trial to
evaluate the immune response, safety and reactogenicity of an
RSVPreF3 OA investigational vaccine when co-administered with FLU
aQIV (inactivated influenza vaccine – adjuvanted) in adults
aged 65 years and above
|
Trial
start:
Q4
2022
Primary
data reported:
Q2
2023
|
Complete;
data analysis ongoing
|
|
RSV
OA=ADJ-018
(Adults
50-59 years)
NCT05590403
|
III
|
A phase
III, observer-blind, randomised, placebo-controlled trial to
evaluate the non-inferiority of the immune response and safety of
the RSVPreF3 OA investigational vaccine in adults 50-59 years of
age, including adults at increased risk of respiratory syncytial
virus lower respiratory tract disease, compared to older adults
≥60 years of age
|
Trial
start:
Q4
2022
Primary
data reported:
Q4
2023
|
Complete;
primary endpoint met
|
|
RSV
OA=ADJ-019
(Adults
≥ 60 years old)
NCT05879107
|
III
|
An
open-label, randomised, controlled, multi-country trial to evaluate
the immune response, safety and reactogenicity of RSVPreF3 OA
investigational vaccine when co-administered with PCV20 in adults
aged 60 years and older
|
Trial
start:
Q2
2023
|
Complete
|
|
RSV
OA=ADJ-023
(Immunocompromised
Adults 50-59 years)
NCT05921903
|
IIb
|
A
randomised, controlled, open-label trial to evaluate the immune
response and safety of the RSVPreF3 OA investigational vaccine in
adults (≥50 years of age) when administered to lung and renal
transplant recipients comparing one versus two doses and compared
to healthy controls (≥50 years of age) receiving one
dose
|
Trial
start:
Q3
2023
Primary
data reported:
Q4
2024
|
Active,
not recruiting; primary endpoint met
|
Key
phase III trials for Arexvy
(continued):
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RSV-OA=ADJ-020
(Adults
aged >=50 years of age)
NCT05966090
|
III
|
A study
on the safety and immune response of investigational RSV OA vaccine
in combination with herpes zoster vaccine in healthy
adults
|
Trial
start:
Q3
2023
Primary
data reported:
Q3
2024
|
Complete;
primary endpoint met
|
|
RSV-OA=ADJ-013
(Adults
aged 50 years and above)
NCT06374394
|
III
|
An
open-label, randomized, controlled study to evaluate the immune
response, safety and reactogenicity of RSVPreF3 OA investigational
vaccine when co-administered with a COVID-19 mRNA
vaccine
|
Trial
start:
Q2
2024
|
Active,
not recruiting
|
|
RSV
OA=ADJ-025
(Adults,
18-49 years of age, at increased risk for RSV disease and older
adult participants, >=60 YOA)
NCT06389487
|
IIIb
|
An
open-label study to evaluate the non-inferiority of the immune
response and to evaluate the safety of the RSVPreF3 OA
investigational vaccine in adults 18-49 years of age at increased
risk for Respiratory Syncytial Virus disease, compared to older
adults >=60 years of age
|
Trial
start:
Q2
2024
Primary
data reported:
Q3
2024
|
Active,
not recruiting
|
|
RSV
OA=ADJ-021
(Adults
aged 60 years and above)
NCT06551181
|
III
|
A study
on the immune response, safety and the occurrence of Respiratory
Syncytial Virus (RSV)-associated respiratory tract illness after
administration of RSV OA vaccine in adults 60 years and
older
|
Trial
start:
Q3
2024
|
Recruiting
|
|
RSV
OA=ADJ-012
(Adults
aged 60 years and above)
NCT06534892
|
IIIb
|
An
Extension and Crossover Vaccination Study on the Immune Response
and Safety of a Vaccine Against Respiratory Syncytial Virus Given
to Adults 60 Years of Age and Above Who Participated in RSV
OA=ADJ-006 Study
|
Trial
start:
Q3
2024
|
Recruiting
|
bepirovirsen (HBV ASO)
Bepirovirsen,
a triple-action antisense oligonucleotide, is a potential new
treatment option for people with chronic hepatitis B (CHB) that has
been granted Fast Track designation by the US FDA and SENKU
designation by the Japanese Ministry of Health, Labour and Welfare
in Japan for the treatment of CHB. To further expand development in
novel sequential regimens, GSK has entered an agreement for an
exclusive worldwide license to develop and commercialise
daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989), an
investigational hepatitis B virus-targeted small interfering
ribonucleic acid (siRNA) therapeutic. This agreement provides an
opportunity to investigate a novel sequential regimen to pursue
functional cure in an even broader patient population with
bepirovirsen.
Key
trials for bepirovirsen:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
B-Well
1 bepirovirsen in nucleos(t)ide treated patients (chronic hepatitis
B)
NCT05630807
|
III
|
A
multi-centre, randomised, double-blind, placebo-controlled trial to
confirm the efficacy and safety of treatment with bepirovirsen in
participants with chronic hepatitis B virus
|
Trial
Start:
Q1
2023
|
Active,
not recruiting
|
|
B-Well
2 bepirovirsen in nucleos(t)ide treated patients (chronic hepatitis
B)
NCT05630820
|
III
|
A
multi-centre, randomised, double-blind, placebo-controlled trial to
confirm the efficacy and safety of treatment with bepirovirsen in
participants with chronic hepatitis B virus
|
Trial
Start:
Q1
2023
|
Active,
not recruiting
|
|
B-United
bepirovirsen sequential therapy with daplusiran/tomligisiran in
nucleos(t)ide treated patients (chronic hepatitis B)
NCT06537414
|
IIb
|
A
multi-centre, randomized, partially placebo-controlled,
double-blind study to investigate the safety and efficacy of
sequential therapy with daplusiran/tomligisiran followed by
bepirovirsen in participants with chronic hepatitis B virus on
background nucleos(t)ide analogue therapy
|
Trial
start:
Q4
2024
|
Recruiting
|
gepotidacin (bacterial topoisomerase inhibitor)
Gepotidacin
is an investigational bactericidal, first-in-class antibiotic with
a novel mechanism of action for the treatment of uncomplicated
urinary tract infections (uUTI) and urogenital gonorrhoea. Positive
data from three pivotal trials demonstrate its potential to provide
a new oral treatment option for patients, including those with drug
resistant infections. Gepotidacin is currently under Priority
Review by the US FDA. A decision on approval is expected in March
2025. Filings for gonorrhoea are expected to follow later in 2025.
If approved, gepotidacin could be the first in a new class of oral
antibiotics in uUTI in over 20 years.
Key
phase III trials for gepotidacin:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
EAGLE-1
(uncomplicated urogenital gonorrhoea)
NCT04010539
|
III
|
A
randomised, multi-centre, open-label trial in adolescent and adult
participants comparing the efficacy and safety of gepotidacin to
ceftriaxone plus azithromycin in the treatment of uncomplicated
urogenital gonorrhoea caused by Neisseria gonorrhoeae
|
Trial
start:
Q4
2019
Data
reported:
Q1
2024
|
Complete;
primary
endpoint met
|
|
EAGLE-2
(females with uUTI / acute cystitis)
NCT04020341
|
III
|
A
randomised, multi-centre, parallel-group, double-blind,
double-dummy trial in adolescent and adult female participants
comparing the efficacy and safety of gepotidacin to nitrofurantoin
in the treatment of uncomplicated urinary tract infection (acute
cystitis)
|
Trial
start:
Q4
2019
Data
reported:
Q2
2023
|
Complete;
primary endpoint met
|
|
EAGLE-3
(females with uUTI / acute cystitis)
NCT04187144
|
III
|
A
randomised, multi-centre, parallel-group, double-blind,
double-dummy trial in adolescent and adult female participants
comparing the efficacy and safety of gepotidacin to nitrofurantoin
in the treatment of uncomplicated urinary tract infection (acute
cystitis)
|
Trial
start:
Q2
2020
Data
reported:
Q2
2023
|
Complete;
primary endpoint met
|
MenABCWY vaccine candidate
GSK’s
5-in-1 meningococcal ABCWY (MenABCWY) vaccine candidate combines
the antigenic components of its two well-established meningococcal
vaccines with demonstrated efficacy and safety profiles:
Bexsero (Meningococcal
Group B Vaccine) and Menveo
(Meningococcal Groups A, C, Y, and W-135). Combining the protection
offered by these vaccines aims to reduce the number of injections,
simplifying immunisation and potentially increasing series
completion and vaccination coverage of adolescents and young adults
in the US. A Biologics License Application (BLA) is currently under
review by the US FDA with a Prescription Drug User Fee Act (PDUFA)
action date of 14 February 2025.
Key
trials for MenABCWY vaccine candidate:
|
|
|
|
|
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
MenABCWY
– 019
NCT04707391
|
IIIb
|
A
randomised, controlled, observer-blind trial to evaluate safety and
immunogenicity of GSK’s meningococcal ABCWY vaccine when
administered in healthy adolescents and adults, previously primed
with meningococcal ACWY vaccine
|
Trial
start:
Q1
2021
Data
reported:
Q1
2024
|
Complete;
primary endpoints met
|
|
MenABCWY
– V72 72
NCT04502693
|
III
|
A
randomised, controlled, observer-blind trial to demonstrate
effectiveness, immunogenicity, and safety of GSK's meningococcal
Group B and combined ABCWY vaccines when administered to healthy
adolescents and young adults
|
Trial
start:
Q3
2020
Data
reported:
Q1
2023
|
Complete;
primary endpoints met
|
Reporting
definitions
CAGR (Compound annual growth rate)
CAGR is
defined as the compound annual growth rate and shows the annualised
average rate for growth in sales and core operating profit between
2021 to 2026, assuming growth takes place at an exponentially
compounded rate during those years.
CER and AER growth
In
order to illustrate underlying performance, it is the Group’s
practice to discuss its results in terms of constant exchange rate
(CER) growth. This represents growth calculated as if the exchange
rates used to determine the results of overseas companies in
Sterling had remained unchanged from those used in the comparative
period. CER% represents growth at constant exchange rates. For
those countries which qualify as hyperinflationary as defined by
the criteria set out in IAS 29 ‘Financial Reporting in
Hyperinflationary Economies’ (Argentina and Turkey) CER
growth is adjusted using a more appropriate exchange rate
reflecting depreciation of their respective currencies in order to
provide comparability and not to distort CER growth
rates.
£%
or AER% represents growth at actual exchange rates.
Core Operating Margin
Core
Operating margin is Core operating profit divided by
turnover.
COVID-19 solutions
COVID-19
solutions include the sales of pandemic adjuvant and other COVID-19
solutions principally during the years from 2020-2023 and includes
vaccine manufacturing and Xevudy and the associated costs but
does not include reinvestment in R&D. This categorisation is
used by management who believe it is helpful to investors through
providing clarity on the results of the Group by showing the
contribution to growth from COVID-19 solutions during this
period.
Free cash flow
Free
cash flow is defined as the net cash inflow/outflow from operating
activities less capital expenditure on property, plant and
equipment and intangible assets, contingent consideration payments,
net finance costs, and dividends paid to non-controlling interests,
contributions from non-controlling interests plus proceeds from the
sale of property, plant and equipment and intangible assets, and
dividends received from joint ventures and associates. The measure
is used by management as it is considered a good indicator of net
cash generated from business activities (excluding any cash flows
arising from equity investments, business acquisitions or disposals
and changes in the level of borrowing) available to pay
shareholders dividends and to fund strategic plans. Free cash flow
growth is calculated on a reported basis. A reconciliation of net
cash inflow from operations to free cash flow from operations is
set out on page 40.
Free cash flow conversion
Free
cash flow conversion is free cash flow from operations as a
percentage of profit attributable to shareholders.
General Medicines
General
Medicines are usually prescribed in the primary care or community
settings by general healthcare practitioners. For GSK, this
includes medicines for inhaled respiratory, dermatology,
antibiotics and other diseases.
Non-controlling interest
Non-controlling
interest is the equity in a subsidiary not attributable, directly
or indirectly, to a parent.
Percentage points
Percentage
points of growth which is abbreviated to ppts.
RAR (Returns and Rebates)
GSK
sells to customers both commercial and government mandated
contracts with reimbursement arrangements that include rebates,
chargebacks and a right of return for certain pharmaceutical
products principally in the US. Revenue recognition reflects
gross-to-net sales adjustments as a result. These adjustments are
known as the RAR accruals and are a source of significant
estimation uncertainty and fluctuation which can have a material
impact on reported revenue from one accounting period to the
next.
Risk adjusted sales
Pipeline
risk-adjusted sales are based on the latest internal estimate of
the probability of technical and regulatory success for each asset
in development.
Specialty Medicines
Specialty
Medicines are typically prescription medicines used to treat
complex or rare chronic conditions. For GSK, this comprises
medicines for infectious diseases, HIV, Respiratory/Immunology and
Other, and Oncology.
Total Net debt
Net
debt is defined as total borrowings less cash, cash equivalents,
liquid investments, and short-term loans to third parties that are
subject to an insignificant risk of change in value. The measure is
used by management as it is considered a good indicator of GSK's
ability to meet its financial commitments and the strength of its
balance sheet.
Total Net debt/Core EBITDA ratio
Core
EBITDA is defined as Total operating profit excluding adjusting
items and core depreciation and amortisation (as described on
page 41) and includes the share of after tax losses on associates.
Core depreciation is total depreciation less depreciation arising
as part of major restructuring and is disclosed as part of
adjusting items. Core amortisation arises from computer software
and internally capitalised R&D development costs. Total Net
debt is defined above. The ratio is Total Net debt expressed as a
multiple of Core EBITDA which demonstrates a key leverage metric
which assesses the strength of the balance sheet.
Total and Core results
Total
reported results represent the Group’s overall performance.
GSK uses a number of non-IFRS measures to report the performance of
its business. Core results and other non-IFRS measures may be
considered in addition to, but not as a substitute for or superior
to, information presented in accordance with IFRS. Core results are
defined on page 17 and other non-IFRS measures are defined in pages
50 and 51.
Turnover excluding COVID-19 solutions
Turnover excluding COVID-19 solutions excludes the impact of sales
of pandemic adjuvant within Vaccines and Xevudy within Specialty Medicines related to the
COVID-19 pandemic principally during the years 2020-2023.
Management believes that the exclusion of the impact of these
COVID-19 solutions sales aids comparability in the reporting
periods and understanding of GSK’s growth including by region
versus prior periods.
Total Operating Margin
Total
Operating margin is Total operating profit divided by
turnover.
Total Earnings per
share
Unless
otherwise stated, Total earnings per share refers to Total basic
earnings per share.
Working capital
Working
capital represents inventory and trade receivables less trade
payables.
Brand names and partner
acknowledgements: brand names appearing in italics throughout this
document are trademarks of GSK or associated companies or used
under licence by the Group.
Guidance and Outlooks, assumptions
and cautionary statements
2025 Guidance
GSK
expects its turnover to increase between 3 to 5 per cent and Core
operating profit to increase between 6 to 8 per cent. Core earnings
per share is expected to increase between 6 to 8 per cent. This
guidance is provided at CER.
The
Core earnings per share guidance assumes that we will implement our
£2 billion share buyback programme over the next 18
months.
The
Group has made planning assumptions that we expect turnover for
Specialty Medicines to increase by a low double-digit per cent,
Vaccines to decrease by a low-single digit per cent, and General
Medicines to be broadly stable.
2021-2026 and 2031 Outlooks
By
2031, GSK now expects to achieve sales of more than £40
billion on a risk-adjusted basis and at CER. This further increase
reflects the inclusion of Blenrep, the significant phase III
progress since last year and multiple launch opportunities in the
2025 to 2031 period.
As
before, we have further upside potential from our early-stage
pipeline and prospective business development.
There
is no change to our outlooks for 2021-2026. GSK continues to expect
sales to grow more than 7% on a CAGR basis and Core operating
profit to increase more than 11%, on the same basis. Core operating
profit margin in 2026 continues to be expected to be more than
31%.
These
outlooks are provided at CER and exclude any contribution from
COVID-19 related solutions.
Assumptions and basis of preparation related to 2025 Guidance,
2021-26 and 2031 Outlooks
In
outlining the guidance for 2025, and outlooks for the period
2021-26 and for 2031, the Group has made certain assumptions about
the macro-economic environment, the healthcare sector (including
regarding existing and possible additional governmental legislative
and regulatory reform), the different markets and competitive
landscape in which the Group operates and the delivery of revenues
and financial benefits from its current portfolio, its development
pipeline and restructuring programmes.
2025 Guidance
These
planning assumptions as well as operating profit and earnings per
share guidance and dividend expectations assume no material
interruptions to supply of the Group’s products, no material
mergers, acquisitions or disposals, no material litigation or
investigation costs for the Company (save for those that are
already recognised or for which provisions have been made) and no
change in the Group’s shareholdings in ViiV Healthcare. The
assumptions also assume no material changes in the healthcare
environment or unexpected significant changes in pricing or trade
policies as a result of government or competitor action. The 2025
guidance factors in all divestments and product exits announced to
date.
2021-26 and 2031 Outlooks
The
assumptions for GSK’s revenue, Core operating profit, Core
operating margin and cash flow outlooks, updated 2031 revenue
outlook and margin expectations through dolutegravir loss of
exclusivity assume the delivery of revenues and financial benefits
from its current and development pipeline portfolio of medicines
and vaccines (which have been assessed for this purpose on a
risk-adjusted basis, as described further below); regulatory
approvals of the pipeline portfolio of medicines and vaccines that
underlie these expectations (which have also been assessed for this
purpose on a risk-adjusted basis, as described further below); no
material interruptions to supply of the Group’s products;
successful delivery of the ongoing and planned integration and
restructuring plans; no material mergers, acquisitions or disposals
or other material business development transactions; no material
litigation or investigation costs for the company (save for those
that are already recognised or for which provisions have been
made); and no change in the shareholdings in ViiV Healthcare. GSK
assumes no premature loss of exclusivity for key products over the
period.
The
assumptions for GSK’s revenue, Core operating profit, Core
operating margin and cash flow outlooks, updated 2031 revenue
outlook and margin expectations through dolutegravir loss of
exclusivity also factor in all divestments and product exits
announced to date as well as material costs for investment in new
product launches and R&D. Risk- adjusted sales includes sales
for potential planned launches which are risk-adjusted based on the
latest internal estimate of the probability of technical and
regulatory success for each asset in development.
Notwithstanding
our guidance, outlooks and expectations, there is still uncertainty
as to whether our assumptions, guidance, outlooks and expectations
will be achieved.
All
outlook statements are given on a constant currency basis and use
2024 average exchange rates as a base (£1/$1.28,
£1/€1.18, £1/Yen 193).
Assumptions and cautionary statement regarding forward-looking
statements
The
Group’s management believes that the assumptions outlined
above are reasonable, and that the guidance, outlooks, and
expectations described in this report are achievable based on those
assumptions. However, given the forward-looking nature of these
guidance, outlooks, and expectations, they are subject to greater
uncertainty, including potential material impacts if the above
assumptions are not realised, and other material impacts related to
foreign exchange fluctuations, macro-economic activity, the impact
of outbreaks, epidemics or pandemics, changes in legislation,
regulation, government actions or intellectual property protection,
product development and approvals, actions by our competitors, and
other risks inherent to the industries in which we
operate.
This
document contains statements that are, or may be deemed to be,
“forward-looking statements”. Forward-looking
statements give the Group’s current expectations or forecasts
of future events. An investor can identify these statements by the
fact that they do not relate strictly to historical or current
facts. They use words such as ‘anticipate’,
‘estimate’, ‘expect’, ‘intend’,
‘will’, ‘project’, ‘plan’,
‘believe’, ‘target’ and other words and
terms of similar meaning in connection with any discussion of
future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of
contingencies such as legal proceedings, dividend payments and
financial results. Other than in accordance with its legal or
regulatory obligations (including under the Market Abuse
Regulation, the UK Listing Rules and the Disclosure and
Transparency Rules of the Financial Conduct Authority), the Group
undertakes no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.
The reader should, however, consult any additional disclosures that
the Group may make in any documents which it publishes and/or files
with the SEC. All readers, wherever located, should take note of
these disclosures. Accordingly, no assurance can be given that any
particular expectation will be met and investors are cautioned not
to place undue reliance on the forward-looking
statements.
All
guidance, outlooks and expectations should be read together with
the guidance and outlooks, assumptions and cautionary statements in
this Q4 2024 earnings release and in the Group's 2023 Annual Report
on Form 20-F.
Forward-looking
statements are subject to assumptions, inherent risks and
uncertainties, many of which relate to factors that are beyond the
Group’s control or precise estimate. The Group cautions
investors that a number of important factors, including those in
this document, could cause actual results to differ materially from
those expressed or implied in any forward-looking statement. Such
factors include, but are not limited to, those discussed under Item
3.D ‘Risk Factors’ in the Group’s Annual Report
on Form 20-F for 2023. Any forward-looking statements made by or on
behalf of the Group speak only as of the date they are made and are
based upon the knowledge and information available to the Directors
on the date of this report.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date:
February 5, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|